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ABSTRACT 
English 
LIM and SH3 protein 1 (LASP1) is a nucleocytoplasmic scaffolding protein. LASP1 
interacts with various cytoskeletal proteins via its domain structure and is known to 
participate in physiological processes of cells. In the present study, a detailed 
investigation of the expression pattern of LASP1 protein in normal skin, melanocytic nevi 
and melanoma was carried out and the melanocyte–specific function of LASP1 was 
analyzed. LASP1 protein was identified in stratum basale of skin epidermis and a very 
high level was detected in nevi, the benign tumor of melanocyte. In the highly 
proliferative basal cells, an additional distinct nuclear localization of the protein was 
noted. In different tumor entities, an elevated LASP1 expression and nuclear localization, 
correlated positively with malignancy and tumor grade. However, LASP1 level was 
determined to be very low in melanoma and even reduced in metastases. Melanoma is 
distinguished as the first tumor tested to date – that displayed an absence of elevated 
LASP1 expression. In addition no significant relation was observed between LASP1 
protein expression and clinicopathological parameters in melanoma.  
The epidermal melanin unit of skin comprises of melanocytes and keratinocytes. 
Melanocytes are specialized cells that synthesize the photo protective coloring pigment, 
melanin inside unique organelles called melanosomes. The presence of LASP1 in 
melanocytes is reported for the first time through this study and the existence was 
confirmed by immunoblotting analysis in cultured normal human epidermal melanocyte 
(NHEM) and in melanoma cell lines, along with the immunohistostaining imaging in 
normal skin and in melanocytic nevi. LASP1 depletion in MaMel2 cells revealed a 
moderate increase in the intracellular melanin level independently of de novo 
melanogenesis, pointing to a partial hindrance in melanin release. Immunofluorescence 
images of NHEM and MaMel2 cells visualized co-localization of LASP1 with dynamin 
and tyrosinase concomitant with melanosomes at the dendrite tips of the cells. 
Melanosome isolation experiments by sucrose density gradient centrifugation clearly 
demonstrated the presence of LASP1 and the melanosome specific markers tyrosinase 
and TRP1 in late stage melanosomes. 
The study identified LASP1 and dynamin as novel binding partners in melanocytes and 
provides first evidence for the existence of LASP1 and dynamin (a protein well–known 
for its involvement in vesicle formation and budding) in melanosomes. Co-localization of 
LASP1 and dynamin along the dendrites and at the tips of the melanocytes indicates a 
potential participation of the two proteins in the membrane vesicle fission at the plasma 
membrane. 
In summary, a possible involvement of LASP1 in the actin–dynamin mediated membrane 
fission and exocytosis of melanin laden melanosome vesicles into the extracellular 
matrix is suggested. 
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German  
LIM und SH3 protein 1 (LASP1) ist ein nukleozytoplasmatischen Gerüstprotein. LASP1 
interagiert über seine Domänenstruktur mit verschiedenen Zytoskelettproteinen und ist 
an physiologischen Prozessen wie Migration und Zellproliferation beteiligt. In der 
vorliegenden Studie wurde eine detaillierte Untersuchung des Expressionsmusters von 
LASP1 in normale Haut, Nävi und Melanom durchgeführt und die Melanozyten-
spezifische Funktion des Proteins analysiert. 
LASP1 konnte durch immunhistologische Färbungen im Stratum basale der Epidermis 
und in hoher Konzentration in Nävi (gutartige Tumore der Melanozyten) nachgewiesen 
werden, während die Expression in Melanom und Metastasen sehr gering ist. Auch 
wurde kein signifikanter Zusammenhang zwischen der LASP1 Proteinexpression in 
Melanomen und den klinisch-pathologischen Parametern bei 58 Patienten festgestellt. 
Dies steht im Gegensatz zu allen bisher getesteten Tumoren (u.a. Brust, HCC und 
Medulloblastom), bei der eine  erhöhte LASP1 Expression in den Tumoren beobachtet 
wurde, die mit dem Tumorgrad korrelierte.  
Die hochproliferativen Basalzellen der Epidermis bestehen aus Keratinozyten und 
Melanozyten und  weisen, im Gegensatz zu Nävi und Melanomzellen, eine deutliche 
Kernlokalisation des LASP1 Proteins auf. Melanozyten sind spezialisierte Zellen, die das 
UV-Schutzfarbpigment Melanin in einzigartigen Organellen, genannt Melanosomen, 
synthetisieren. Die Expression von LASP1 in diesen Melanozyten konnte zum ersten 
Mal in dieser Studie nachgewiesen werden. Immunfluoreszenzaufnahmen  und Western 
Blots mit kultivierten normalen menschlichen epidermalen Melanozyten (NHEM) und 
Melanom-Zelllinien bestätigen die LASP1 Expression. Funktionelle Experimente mit 
LASP1 depletierten Zellen zeigen eine erhöhte Melaninkonzentration, die unabhängig 
von der de novo Melanogenese ist. Immunfluoreszenaufnahmen visualisieren eine Ko-
Lokalisation von LASP1 mit Tyrosinase an den Melanosomen in den Zellausläufern von 
pigmentierten MaMel2 Zellen. Eine Auftrennung der einzelnen Melanosomenstadien 
durch Saccharose-Dichtegradienten-Zentrifugation erlauben die Detektion von LASP1 
mit Dynamin,  TRP1 und Tyrosinase in späten Stadium IV Melanosomen.  
Die vorliegende Studie liefert den ersten Beweis für die Existenz von Dynamin (einem für 
die Vesikelbildung essentiellem Protein) in Melanosomen und identifiziert Dynamin als 
neuartigen Bindungspartner von LASP1 in Melanozyten. Die Ko-Lokalisierung LASP1 
und Dynamin entlang der Dendriten und in den Spitzen der Melanozyten weist auf eine 
mögliche Beteiligung beider Proteine an der Melanosomen-Vesikel-Abspaltung an der 
Plasmamembran hin.   
Zusammenfassend lässt sich sagen, dass LASP1 an der Actin-Dynamin vermittelten 
Exocytose von Melanin-beladenen Melanosomvesikeln in die Extrazellulärmatrix beteiligt 
ist. 
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Section I – Cell physiology 
1. Introduction 
Periodic exposure of human skin to ultraviolet radiation (UVR) is regarded as the main 
causative factor in the induction of skin cancer. The most important photo protective 
factor ̶  melanin serves as a barrier against UVR induced DNA damage of skin cells and 
also acts as an antioxidant and has radical scavenging properties. Melanin granules are 
produced by specialized cells called melanocytes and are synthesized and packaged 
inside unique membrane bound organelles termed melanosomes. 
Melanosome biogenesis occurs through four morphologically different stages and the 
mature melanosomes are transported towards the cell dendrite tips and eventually 
released into the extracellular matrix. The melanosome vesicles are then phagocytized 
by keratinocytes and the melanin forms a nuclear cap and protects the DNA of the cell. 
The progression of melanosomes through the different stages and the excision of 
melanin laden melanosome vesicles at the plasma membrane are regulated by 
interdependent interactions of molecular motor proteins, multi–protein assemblies and 
cytoskeletal rearrangements.  
A single melanocyte is responsible to deliver melanin to a large number of keratinocytes 
(~40) through extensive and elaborated cytoplasmic extensions or dendrites, which 
spread throughout the intracellular spaces of the lower epidermis. On account of the less 
number of melanocytes, the transfer of melanosomes from melanocytes to keratinocytes 
is considered as the crucial step in the whole process. 
LIM and SH3 protein 1 (LASP1) has been recently identified as a novel protein 
expressed in cells of the epidermal basal layer of skin. It is a cytoskeletal scaffolding 
protein preferentially localized at focal contacts and along the membrane edges of the 
cell. Moreover, studies have shown LASP1 binding to various cytoskeletal proteins and 
also demonstrated its participation in various secretory processes, for instance secretory 
HCl response in gastric parietal cells.  
Although the biogenesis of melanosomes and the synthesis and release of melanin 
granules have been studied extensively, the mechanisms are still less characterized. 
The expression of LASP1 in the epidermal basal layer of skin, comprising of 
melanocytes and keratinocytes together with previous reports describing LASP1 protein 
participation in granula release prompted us to investigate the expression pattern of 
LASP1 in skin tissue samples as well as in cultured melanocyte specific cell lines and 
also to research its contribution in melanogenesis.  
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2. Review of literature 
2. 1.  LIM and SH3 protein 1 (LASP1) 
(a). General description of human LASP1 
LASP1 was initially identified as pp40, a phosphoprotein that migrates on SDS−PAGE 
gels with an apparent molecular mass of ∼40 kDa (Chew and Brown 1987). Later, pp40 
was isolated, partially sequenced and cloned by the same group and shown to be 
homologous to the predicted protein product of the human gene, metastatic auxiliary 
lymph nodes (MLN50). Northern blot analysis revealed an approximately 4.0 kb long 
mRNA of MLN50 that is ubiquitously expressed at basal levels in normal tissues. 
Sequence analysis showed that MLN50 encoded a putative protein with a LIM motif at its 
amino terminus and a Src homology 3 (SH3) domain at its C−terminal part. This domain 
organization defined a new LIM protein subfamily characterized by the combined 
presence of LIM and SH3 domains. Thereupon, MLN50 is termed accordingly: LIM and 
SH3 Protein 1 − in short: LASP1 (Tomasetto, Moog-Lutz et al. 1995; Schreiber, Masson 
et al. 1998). LASP1 gene was mapped to chromosomal region 17q11 ̶ q21.3, a region 
altered in 20−30% of all breast cancers suggesting that it could play a role in tumor 
development and metastases. A schematic representation of the domain organization of 
LASP1 protein is depicted in Figure 1. It encodes a protein of 261 amino acids. (Chew, 
Chen et al. 2002; Keicher, Gambaryan et al. 2004).  
 
Figure 1: Schematic representation of LASP1 protein domain structure. Linear 
representation of the domain organization of LASP1 based on its three–dimensional structure, as 
revealed by crystallographic studies (numbers indicate amino acid position within the primary 
sequence of human LASP1). It contains an amino terminal cysteine–rich, zinc finger LIM domain 
and a carboxyl terminal Src homology 3 (SH3) domain. LASP1 interacts to the proline–rich motifs 
of other proteins through the SH3 domain. It has two short nebulin–like repeats (R1 and R2), 
each comprised of 35 residues that allow binding to F–Actin, a Nuclear Export Signal (NES) and 
two specific kinase phosphorylation sites at serine 146 (PKA and PKG) and tyrosine 171 (SRC 
and cABL).  
Review of literature 
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LASP1 is ubiquitously expressed, albeit differentially distributed, in tissues including 
platelets, brain, heart, kidneys, lung, liver, endothelial cells, smooth muscle cells, and 
fibroblasts (Butt, Gambaryan et al. 2003). In brain, LASP1 is expressed in cortex, 
hippocampus and cerebellum and also densely concentrated at the postsynaptic 
membrane of dendritic spines (Grunewald and Butt 2008). Studies have also revealed a 
particularly prominent expression of this protein among various secretory tissues and in 
other F–Actin rich ion transporting cells e.g. gastric parietal cells, salivary duct cells, 
certain distal tubule and collecting duct cells in the kidney and in ductal cells of the 
exocrine pancreas (Chew, Chen et al. 2002). 
The actin–binding protein LASP1 is predominantly found at multiple sites of cytoplasmic 
dynamic actin assembly such as focal contacts, lamellipodia, membrane ruffles, 
pseudopodia and podosomes where it interacts with a number of motility–associated 
proteins (Grunewald, Kammerer et al. 2007; Stolting, Wiesner et al. 2012; Mihlan, Reiss 
et al. 2013).  
Comparing with normal tissues, tumor cells display an elevated level of LASP1 
expression and also a LASP1–positive nuclei hypothesising a role of the protein in 
transcription or serving as a transcriptional cofactor. Recently several data’s have 
published that substantiates LASP1 function as a signal transducer and mediates the 
functions of various other genes like insulin–like growth factor–I receptor (IGF–IR) in 
cancer progression [reviewed in (Orth, Cazes et al. 2015)].  
(b). Domain structure and interacting partners of LASP1 
LIM domain:  
The three–dimensional structure of the domain at the N–terminal half of LASP1 is 
superimposable with the zinc modules of the chicken CRP and rat CRIP LIM proteins, 
confirming that this cysteine–rich motif present in LASP1 is literally a LIM domain 
(Schreiber, Masson et al. 1998). The LIM domain is comprised of two zinc–binding 
modules and highly conserved eight cysteine and histidine residues (C–X2–C–X16/23–
H–X2–C–X2–C–X2–C–X16/21–C–X2/3–C/D/H) and functions as a modular molecular 
binding interface to mediate protein–protein interactions. The chemokine receptors 
(CXCR) 1–4 have been demonstrated to interact with LASP1 via its LIM domain 
(Raman, Sai et al. 2010; He, Yin et al. 2013). The presence of LIM domains is 
considered as a hallmark of proteins that can associate with actin cytoskeleton and are 
predicted to link with the transcription machinery (Kadrmas and Beckerle 2004).  
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SH3 domain: 
LASP1 participates in protein–protein interaction by binding to the proline–rich SH3 
motifs of other proteins. The SH3 domain regulates protein–protein interaction and 
facilitates cellular localization during signal transduction (Keicher, Gambaryan et al. 
2004). Investigations have proved LASP1 specially interacts with a number of motility–
associated, focal adhesion proteins including zyxin (Li, Zhuang et al. 2004), palladin 
(Rachlin and Otey 2006), LPP (Keicher, Gambaryan et al. 2004), pro-interleukin-16 (Pro-
IL-16), vasodilator stimulated phosphoprotein (VASP) and dynamin via SH3 domain 
(Grunewald, Kammerer et al. 2007; Zhang, Chen et al. 2009; Tang, Kong et al. 2012; 
He, Yin et al. 2013) and most of them are involved in actin filament dynamics and 
pseudopodial elongation. Mutation analysis of LASP1 demonstrates that its SH3 domain 
is necessary for pseudopodial extension and invasion (Spence, McGarry et al. 2006).  
Zyxin, a focal adhesion protein is a prime candidate in the list of binding partners of 
LASP1 (Li, Zhuang et al. 2004). It is predominantly localized at focal adhesion plaques 
but also has the ability to shuttle into the nucleus and is crucial for actin filament 
polymerization in mammalian cells (Grunewald and Butt 2008). Interaction of the C–
terminal SH3 domain of LASP1 with the proline rich region of zyxin has been confirmed 
using the two–hybrid system (Li, Zhuang et al. 2004). Under normal conditions, zyxin is 
mainly associated with the plasma membrane and with focal contacts by interacting to 
LASP1. Silencing of LASP1 dramatically influences zyxin distribution and also 
demonstrated that the phosphorylation of LASP1 at Ser–146 modulates the interaction 
with zyxin (Mihlan, Reiss et al. 2013). 
ZO2 is a multidomain scaffolding protein that interacts with several cell signalling 
proteins, to the actin cytoskeleton and to gap, tight and adherens junction protein 
(Gonzalez-Mariscal, Bautista et al. 2012). LASP1 lacks a known nuclear import signal 
and it was reported recently that ZO2 regulates nuclear transport of LASP1 (Mihlan, 
Reiss et al. 2013).  
LPP, a shuttle protein and transcription factor that is ubiquitously expressed in all 
tissues, transduces signals from focal contacts to the nucleus, and interacts with LASP1 
through proline rich motifs (Grunewald and Butt 2008; Grunewald, Pasedag et al. 2009; 
Zhang, Chen et al. 2009; Frietsch, Grunewald et al. 2010). Pro-IL-16 is present in the 
cytoplasm as well as in the nucleus of T–cells. Binding of LASP1 to Pro-IL-16 by means 
of SH3 domain indicates a potential role of LASP1 in modifying T–lymphocyte 
proliferation since it is highly expressed in T–lymphocytes as well (Grunewald and Butt 
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2008). LASP1 interacts with palladin via the SH3 domain and this interaction is known to 
mediate the binding of LASP1 to actin stress fibres. Palladin knockdown results in the 
loss of LASP1 at actin stress fibres and redirection of the protein to focal contacts 
without changing actin filaments (Rachlin and Otey 2006).  
Nebulin repeats: 
The N–terminal LIM domain is followed by two nebulin–like repeats called R1 and R2, 
each containing 35 residues that enable protein binding to F–Actin (Schreiber, Masson 
et al. 1998). Furthermore, the presence of nebulin–like actin binding repeats along with 
the co-immunoprecipitation of actin with GST–LASP1 fusion protein confirms the 
interaction of LASP1 with the actin cytoskeleton (Chew, Parente et al. 2000). Even 
though LASP1 seems to be the most distantly related nebulin family member, the protein 
still participates in the stabilization of cytoskeletal structures like actin filaments and focal 
adhesions and is also found to be essential for other cellular activities (Chew, Chen et al. 
2002). LASP1 by means of nebulin repeats also binds to Krp1, a focal adhesion protein 
involved in pseudopodial elongation and cell migration (Spence, McGarry et al. 2006; 
Gray, McGarry et al. 2009).  
Linker region: 
The actin–binding motifs are followed by a linker–region with distinguished precise 
phosphorylation residues at serine/threonine and tyrosine. Various researches have 
demonstrated that the subcellular distribution and physiological activity of LASP1 is 
controlled by phosphorylation at several sites. For example, LASP1 phosphorylation in 
fibroblasts prevents protein localization at focal contacts and promotes its perinuclear 
enrichment (Keicher, Gambaryan et al. 2004).   
(c). LASP1 phosphorylation  
Human LASP1 is phosphorylated by cyclic adenosine monophosphate– and cyclic 
guanosine monophosphate– dependent protein kinase (PKA and PKG) at serine–146 
(Ser–146) (Butt, Gambaryan et al. 2003). Studies in pancreas, intestine and gastric 
mucosa have manifested, LASP1 as a signalling molecule that gets phosphorylated 
upon elevation of cAMP (Chew, Chen et al. 2002). Moreover, phosphorylation of LASP1 
at Ser–146 by PKA and PKG resulted in translocation of the protein from membrane to 
cytosol (Grunewald, Kammerer et al. 2007; Mihlan, Reiss et al. 2013). Figure 2 
demonstrates the localization and shuttling of LASP1 protein after phosphorylation in 
cells. 
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Figure 2: LASP1 distribution and PKA– induced trans-localization. Under basal conditions, 
LASP1 localized at the plasma membrane and focal contacts binding with F-Actin, zyxin and ZO2 
and also partially shuttles between the cytoplasm and the nucleus. Upon phosphorylation at Ser-
146, LASP1 forms a complex with ZO2 and translocate into the nucleus. 
Source: http://www.nature.com/onc/journal/v32/n16/full/onc2012216a.html  
Investigations in gastric parietal cells demonstrate histamine and forskolin mediated 
LASP1 phosphorylation by PKA and concomitant a partial redistribution of LASP1 from 
the cortical membrane to the intracellular canalicular region, a site of active HCl 
secretion, thus indicating a regulatory role of LASP1 in actin cytoskeleton plasticity and 
vesicle trafficking (Chew, Chen et al. 2002). Moreover, experiments have shown LASP1 
associates with F–Actin in a phosphorylation–dependent manner and also binds to and 
co-localizes with endocytosis–associated proteins like dynamin2 (Okamoto, Li et al. 
2002) to regulate HCl secretion.  
In 2003, Butt et al. determined LASP1 as a novel substrate of PKG in human platelets. 
Studies with human LASP1 mutants identified Ser–146 as the specific phosphorylation 
site for PKA and PKG in vivo and also illustrated that phosphorylation of LASP1 at Ser–
146 leads to a redistribution of the actin–bound protein from the tips of the cell 
membrane to the cytosol, accompanied with a reduced cell migration. Additionally, 
experiments analysing the molecular signature in neurons, suggested that after 
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phosphorylation, LASP1 was modified and plays a role in homocysteic acid induced 
neurotoxicity and also showed its involvement in neuronal differentiation and 
development (Grunewald and Butt 2008). 
Therewithal, human LASP1 protein is phosphorylated at tyrosine–171 (Y–171) by 
abelson tyrosine kinase (Abl kinase) and Src kinase, two kinases strongly involved in 
carcinogenesis. In NIH 3T3 cells, phosphorylation of LASP1 at Y–171 is associated with 
loss of LASP1 protein from focal adhesion points, and initiation of cell death with no 
change in the dynamics of migratory processes. In platelets, LASP1 phosphorylation by 
Src kinase is associated with platelet activation, translocation of LASP1 to focal contacts 
and cytoskeleton rearrangements (Grunewald, Kammerer et al. 2007; Grunewald and 
Butt 2008).  
Collectively, LASP1 is an extremely versatile protein because of its ubiquitous 
expression in normal tissues, its interaction with various binding partners and its ability to 
regulate cell structure, physiological processes and cells signalling.  
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2. 2. Melanocytes – the pigment producing cells 
(a). Melanocyte origin, occurrence and function  
The pigment producing melanocytes are primarily residing in the hair follicle, epidermis 
and eye, and are responsible for hair, skin and eye pigmentation (Goding 2007). 
However, the existence of melanocytes has also been confirmed in the inner ear, in the 
nervous system and in heart (Tachibana 1999; Brito and Kos 2008). Besides 
pigmentation, melanocytes are also essential for hearing. In the stria vascularis, 
melanocytes are required for the generation of endolymph–mediated action potentials 
and consequently genetic mutations that lead to loss of melanocytes in the inner ear are 
a major cause of deafness (Steel and Barkway 1989). There are debates that going on 
the chemical structure of melanin, and hence, its precise function may vary between 
distinct sites of melanocytes reside (Goding 2007).  
During embryogenesis epidermal melanocytes derive from the neural crest and migrate 
towards the epidermis, where they reside in the basal layer of skin epidermis in contact 
with keratinocytes (Videira, Moura et al. 2013). Upon UV irradiation keratinocytes 
secrete α–melanocyte stimulating hormone (α–MSH) and other related 
proopiomelanocortin–derived peptides that bind to the melanocortin 1 receptor (MC1R) 
on melanocytes, which subsequently activates the cAMP–PKA pathway and the 
microphthalmia–associated transcription factor (MITF) – a master regulator of 
melanocyte function and melanogenesis, [reviewed in (Vance and Goding 2004; Garcia-
Borron, Sanchez-Laorden et al. 2005)] and thereby initiate melanogenesis.  
Melanogenesis involves several steps like transcription of melanogenic proteins, 
melanosome biogenesis, sorting of melanogenic proteins into melanosomes and 
melanin synthesis, transport of melanosomes to the tips of melanocyte dendrites and 
finally transfer into keratinocytes [reviewed in (Park, Kosmadaki et al. 2009; Sitaram and 
Marks 2012)]. Melanogenesis leads to the production of a high ratio of melanin and are 
considered as the most enigmatic pigments/biopolymers found in nature [reviewed in 
(d'Ischia, Wakamatsu et al. 2013; Besaratinia and Tommasi 2014)].  
(b). Characteristics of melanin 
Melanin is complex hetero polymers produced within specific membrane–bound 
organelles known as melanosomes inside melanocytes (Yamaguchi and Hearing 2006). 
Melanin synthesis and distribution in the epidermis comprises of several phases and is 
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regulated by numerous paracrine and autocrine factors in response to endogenous and 
exogenous stimuli, principally UV irradiation (Park, Kosmadaki et al. 2009).  
In humans, melanin is subclassified into eumelanin a dark black–brown insoluble 
polymer and pheomelanin a light yellow–reddish sulfur containing soluble polymer 
(d'Ischia, Wakamatsu et al. 2013). Diversity of skin pigmentation among different ethnic 
groups is preserved and depends on the ratio of eumelanin to total melanin. The kind of 
melanin production is based on the availability of substrates and the function of 
melanogenesis enzymes (Cichorek, Wachulska et al. 2013).  The amount of the melanin 
pigment varies under different pathological conditions and as well as within different 
species. 
Investigations have reported that melanin has various features which are beneficial to 
the body: UV light absorption and scattering, free radical scavenging, coupled oxidation–
reduction reactions and ion storage (Cichorek, Wachulska et al. 2013). Studies also 
have shown the role of melanin in preserving cell membrane lipids from UV–A induced 
peroxidation. Melanin within the melanosomes also acts as a sink for highly reactive 
oxygen species (ROS), efficiently filters toxic substances and protects tissues from 
oxidative and chemical stress (d'Ischia, Wakamatsu et al. 2013). Unfortunately, melanin 
intermediates as well as melanin itself can enhance UV–induced DNA damage on 
chronic exposures, most likely through the generation of ROS.  
Since melanin has a wide variety of functions, estimation of melanin is essential to have 
a close look on pigment related diseases. Different methods have been used for the 
evaluation of melanin content of specimens from pigmented tissues or from cultured 
cells (Hu 2008). The most popular and relatively simple technique used for the 
measurement of melanin in cultured pigment cells is the spectrophotometric method. 
Various studies have shown the estimation of melanin by dissolving it in 1N NaOH in 
DMSO and incubating at 80oC (Abdel-Naser, Krasagakis et al. 2003).   
(c). Melanosome biogenesis and melanogenesis 
Melanosome formation is a multiplex process and begins with trafficking of a large 
number of pigment cell–specific melanosomal proteins into endosomes leading to the 
gradual transformation into a mature pigment producing organelle. A cascade of proteins 
localized in melanosomes plays an active roles in the structure and function of the 
organelle, either as catalytic entities involved in melanin synthesis such as tyrosinase 
(TYR) and tyrosinase–related proteins (TRP1, TRP2) or as structural proteins important 
for the integrity of melanosomes like Pmel17 (GP100) (Sitaram and Marks 2012). When 
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the processes of melanogenesis gets disturbed, it may lead to different types of 
pigmentation defects, which can be congenital or acquired, permanent or temporary, 
systemic or skin–restricted and has a significant impact on patient’s quality of life 
(Fistarol and Itin 2010). 
Classical electron microscopy studies revealed that melanosomes mature through four 
morphologically distinct stages. The mechanism of melanosome biogenesis is 
schematically illustrated in Figure 3. Stage I melanosomes or pre–melanosomes are 
round, vacuolar domains harboring intraluminal vesicles and irregular arrays of amyloid 
fibrils composed of pigment cell–specific protein Pmel17 (gp100) (Raposo and Marks 
2007; Sitaram and Marks 2012). In stage II melanosomes the fibrils are structured into 
organized striations and the crucial melanosome enzyme, tyrosinase is expressed. 
Stage III melanosomes is characterized by melanin production and deposition onto the 
protein fibrils, giving rise to thick striations while stage IV melanosomes are fully 
melanized and melanin deposits mask the internal matrix. Eventually, fully melanized 
melanosomes are transported to surrounding keratinocytes by elements of the 
cytoskeletal system [reviewed in (Park, Kosmadaki et al. 2009; Cichorek, Wachulska et 
al. 2013)].  
 
Figure 3: Diagrammatic presentation of melanosome maturation. Melanogenesis takes place 
inside melanosomes through four morphologically different stages. Pre–melanosome first 
develops as a vesicle (Stage I), followed by a fibrillar glycoprotein matrix formation and 
expression of tyrosinase and other enzymes of melanogenesis (Stage II). Melanosomes start 
producing melanin that polymerizes and settles on the internal fibrils (Stage III). In the last stage, 
(Stage IV) melanosomes are filled up with melanin.  
Sucrose density gradient centrifugation has been known as a successful method to 
prepare highly purified melanin–laden melanosomes (Watabe, Kushimoto et al. 2005). 
Ultracentrifugation of cellular homogenates layered on top of a 1.0 – 2.0 M sucrose 
gradient allows separation of melanosome stages in different molar zones according to 
the sedimentation rate. Previous analysis showed that 1.0 and 1.2 M sucrose fractions 
contain the early stages while the late stages are present in the 1.6 and 1.8 M gradients 
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(Kushimoto, Basrur et al. 2001; Basrur, Yang et al. 2003). The purified fractions can be 
used for enzymatic and/or proteomic analyses or for structural characterization.  
(d). Melanosome transport from cell center to periphery  
Melanosomes are transferred from the site of synthesis in melanocyte perikariyon along 
the dendrite tips to the periphery and released into the extracellular matrix (Jordens, 
Westbroek et al. 2006). The transport occurs with the help of microtubules (MT) that are 
arranged parallel to the long axis of the dendrite and is regulated by two MT–associated 
motor proteins: kinesins and cytoplasmic dyneins, both forming cross–bridge structures 
and connecting the organelle to the microtubules. The melanosome  transport machinery 
is depicted in Figure 4. Studies examining melanosomal transport suggest that MT–
dependent movement is bidirectional: centrifugal anterograde organelle movement is 
mediated primarily by kinesin (Hara, Yaar et al. 2000), whereas centripetal movement is 
controlled by cytoplasmic dynein (Byers, Yaar et al. 2000). 
 
Figure 4: Melanosomes transport from perinuclear area to the cell periphery. Melanosomes 
are transported bi–directionally during the process of maturation. Microtubules, cortical actin 
network along with molecular motor proteins enables the movement of vesicle. 
Source: http://onlinelibrary.wiley.com/doi/10.1111/j.1600–0749.2006.00329.x/pdf 
It has been reported that, the small GTPase Rab27a recruits effector proteins to the 
melanosome membrane in conjunction with the modular adaptor protein – melanophilin 
and thereby regulating intracellular trafficking events. Rab27a recruits melanophilin and 
myosin Va, a molecular motor, to the melanosome membrane resulting in a tripartite 
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capture complex, which mediates the MT to actin organelle transport. Accordingly, 
melanosomes integrated to the dense cortical actin shell facilitated by myosin Va–
dependent coupling, thus get dispersed and retained in the peripheral dendrites. Thence 
MT and actin track and motor systems jointly foster melanosome transport and retention 
in peripheral dendrites (Raposo and Marks 2007; Hume and Seabra 2011).  
There are several hypotheses describing the transfer of mature melanosomes from 
melanocytes to neighboring keratinocytes: exocytosis, cytophagocytosis, fusion of 
plasma membranes and transfer by membrane vesicles (Figure 5). 
 
Figure 5: Different melanosome transfer mechanisms. Demonstrated four possible 
mechanisms of intercellular melanosome transfer to keratinocytes. 
Source: http://www.sciencedirect.com/science/article/pii/S0955067414000234 
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In the cytophagocytosis model, keratinocyte phagocytizes the melanocyte's 
melanosome–rich dendritic tip, whereas in the membrane fusion model the melanosome 
moves through a transient membrane conduit connecting the cytoplasm of the 
melanocyte and keratinocyte. In the third model, melanosome–rich vesicles shed from 
the melanocyte and are subsequently internalized by the keratinocyte via phagocytosis 
or by membrane fusion. In the fourth mode of transfer, melanocyte releases the 
melanosomes melanin core into the extracellular space via exocytosis, and the 
keratinocyte then internalizes this ‘melanocore’ via phagocytosis (Van Den Bossche, 
Naeyaert et al. 2006; Wu and Hammer 2014). Researches have given strong evidences 
for three and four mechanisms. 
Concluding that melanocytes are cells responsible for the synthesis of melanin inside 
specific organelles termed as melanosomes and the production and dispersion is 
essential for the photoprotection of cells. 
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Section II – Cell oncology 
1. Introduction 
Metastasis is a hallmark of malignant tumors and is responsible for as much as 90% of 
cancer–associated mortality, yet this process remains one of the most baffling facets of 
the cancer pathogenesis. It is well established that metastasis is a complex, multistep 
process, in which malignant cells spread from the tumor of origin to colonize distant 
organs. Tumor cells thus populate and flourish in new tissue habitats and, eventually, 
cause organ dysfunction and cell death. Prevention and management of metastases by 
understanding the voluminous molecular contributors and processes are entailed, and 
are therefore among the key goals in basic and clinical cancer research. 
Cutaneous melanoma (‘henceforth referred to as melanoma’) is a highly malignant 
neoplasm originating from the pigment producing melanocytes in the basal layer of 
epidermis. Melanocytic nevi are benign neoplasms of melanocytic lineage and provide a 
roadway to melanoma. Malignant cutaneous melanoma develops through well–
distinguished phases of tumor progression, including cell growth, invasion and 
metastasis. The worldwide incidence of melanoma has increased over the past few 
decades, with a growing fraction of patients possessing advanced metastatic melanoma 
or being at a high risk of for the disease for which prognosis remains poor despite 
advances in therapies. Under these circumstances, it is essential to discover new 
melanoma therapeutic targets, which would be an over–and–above advantage for the 
adjuvant treatments.  
There are quite a few new molecules involved in carcinogenesis and cancer progression 
that have been discovered in the past few years, and one such protein is LIM and SH3 
protein 1 (LASP1). Whilst LASP1 is expressed at low basal levels virtually in all normal 
tissues, an up–regulation of the protein has been noticed in various cancer entities 
studied hitherto. Besides, researches have shown the involvement of this protein in 
tumor cell proliferation and migration. Moreover, an elevated LASP1 level together with 
nuclear localization positively correlated with malignancy, higher tumor grade and 
metastatic lymph node status [reviewed in (Orth, Cazes et al. 2015)]. LASP1 also serves 
as a prognostic tumor marker. 
Recently LASP1 was identified in human breast epidermal basal cells (Grunewald, 
Kammerer et al. 2007). Therefore, it was of great interest to investigate the influence of 
LASP1 in the development and progression of melanoma.  
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2. Review of literature  
2. 1. LASP1 impact on human cancer 
Decade ago, LASP1 was initially identified from a cDNA library of metastatic axillary 
lymph nodes (MLN) from human breast cancer (Tomasetto, Moog-Lutz et al. 1995). 
Since then, LASP1 was pinpointed in multiple microarray studies that peruse genes 
associated with tumor development and cancer progression [reviewed in (Orth, Cazes et 
al. 2015)]. LASP1 is upregulated in a range of cancers, including breast (Grunewald, 
Kammerer et al. 2006; Grunewald, Kammerer et al. 2007; Frietsch, Grunewald et al. 
2010; Wang, Zheng et al. 2012), prostate (Nishikawa, Goto et al. 2014), ovarian 
(Grunewald, Kammerer et al. 2007),  colorectal (Zhao, Wang et al. 2010; Wang, Li et al. 
2013; Wang, Li et al. 2014), medulloblastoma (Traenka, Remke et al. 2010), 
hepatocellular carcinoma (Wang, Feng et al. 2009; Tang, Kong et al. 2012; Wang, Li et 
al. 2013) and oral carcinoma (Shimizu, Shiiba et al. 2013).  
In the past few years various researches demonstrated the massive influence of LASP1 
in tumor development such as cell proliferation and migration, exploiting different 
strategies including transient overexpression or knockdown of the protein. Several 
studies exhibited  a decreased cell migration and a reduced proliferation followed by 
siRNA–dependent depletion of LASP1 in different cell lines – including breast, ovarian, 
prostrate and  hepatoma cancer cell lines, concomitant with cell cycle arrest in G2/M–
phase (Grunewald and Butt 2008; Frietsch, Grunewald et al. 2010). On the other hand, 
up-regulation of LASP1 increased the migratory activity of non–transformed PTK2 cells 
but had no significant effect on primary human umbilical vein endothelial cell migration 
(Grunewald, Kammerer et al. 2007; Zhang, Chen et al. 2009) with cell cycle arrest in 
G2/M–phase (Grunewald and Butt 2008; Frietsch, Grunewald et al. 2010).  
Interestingly, a prominent nuclear localization of LASP1 protein is noticed in the 
immunohistochemical analysis of breast cancer and medulloblastoma, which correlated 
significantly with tumor size, nodal positivity and a poor long–term survival of the patients 
(Frietsch, Grunewald et al. 2010; Traenka, Remke et al. 2010). The existence of nuclear 
LASP1 was detected and confirmed by confocal microscopy and Western blots of 
cytosolic and nuclear preparations in various breast cancer cell lines. In malignant breast 
cancer, the concentration of PKA is four times higher than in normal cells, therefore the 
up-regulation of LASP1 in breast cancer cells in combination with LASP1 hyper 
phosphorylation by PKA at Ser–146 and subsequent nuclear import might be crucial for 
its oncogenic potential (Mihlan, Reiss et al. 2013).  
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In several studies, an up-regulation of LASP1 has been shown to promote cell migration 
and proliferation. In HCC, LASP1 overexpression contributes to the aggressive 
phenotype of cells and is proposed as an independent novel prognostic indicator (Wang, 
Li et al. 2013). In colorectal cancer (CRC) tissues, LASP1 level is high and has a 
significant relationship with lymph node metastasis and the overall survival of the 
patients (Zhao, Wang et al. 2010). Moreover, LASP1 unveiled effects on metastatic 
dissemination and disease progression with high potential in medulloblastoma (Traenka, 
Remke et al. 2010) and is also reported to have an influence on cell proliferation, 
migration and invasion of the esophageal squamous cell carcinoma (ESCC) (He, Yin et 
al. 2013). Yang et al. validated an increased LASP1 expression in a series of 216 clear 
cell renal cell carcinoma (ccRCC) tissues and also stated this up-regulation is 
significantly associated with large tumor size and worse TNM stage (Yang, Zhou et al. 
2014). 
Recent research in our group identified LASP1 as a novel and overexpressed protein in 
chronic myeloid leukemia (CML) and as a direct substrate of the oncogenic BCR–ABL 
tyrosine kinase in CML. LASP1 is specifically phosphorylated by BCR–ABL at tyrosine–
171. Contradictory to other tumor entities, no nuclear localization is observed in CML 
patients (Frietsch, Kastner et al. 2014).  
2. 1. 1. LASP1 expression regulation in human cancer 
To date, several studies have been carried out to investigate the regulatory mechanisms 
of LASP1 expression, such as the potential tumor suppressor prostate–derived ETS 
factor (PDEF) (Frietsch, Grunewald et al. 2010), urokinase–type plasminogen activator 
(uPA) (Tang, Kong et al. 2012), HBx, a protein encoded by the X gene of HBV genome  
(Tang, Kong et al. 2012), and HIF1α (Zhao, Ren et al. 2015).  
Furthermore, an association between elevated nuclear LASP1 levels and mutations of 
the p53 tumor–suppressor gene is detected in hepatocellular carcinoma. It has been 
shown that LASP1 was repressed by wild–type p53 at the transcriptional level and a 
functional negative p53 mutations led to increased LASP1expression and to a more 
aggressive HCC phenotype (Wang, Feng et al. 2009; Tang, Kong et al. 2012). 
 MicroRNAs (miRNAs), small non-coding RNA molecules– can suppress the expression 
of target genes and are thought to regulate various malignancies. LASP1 expression 
was proven to be regulated by miR–203 (Takeshita, Mori et al. 2012; Wang, Zheng et al. 
2012), miR–133a (Wang, An et al. 2013) and miR–218 (Nishikawa, Goto et al. 2014).  
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2. 2. Melanoma and melanocytic nevi 
Melanoma arises from the malignant transformation of melanocytes, the coloring 
pigment producing cells and in many countries melanoma has become a serious public 
health problem. The key triggers leading to this malignant transformation are considered 
to be multi–factorial and include UV radiation damage and genetic susceptibility (Bastian 
2014). Cutaneous malignant melanoma accounts for 3 to 5 percent of all skin cancers, 
still is responsible for approximately 75 percent of all deaths from skin cancer 
(Shenenberger 2012). 
The steady increase in the incidence of melanoma worldwide is thought to be due to the 
periodic exposure of fair–skinned individuals to intense sunlight and the outspread is 
faster than any other type of cancer (Thompson, Scolyer et al. 2005; Tronnier and 
Mitteldorf 2014). Episodic exposure of skin to ultraviolet radiation can lead to malignancy 
through a sequence of alterations in the skin by direct mutagenic effects on DNA or 
indirectly by stimulating cellular constituents like promoting growth factor production or 
formation of reactive oxygen species of melanin that cause DNA damage and suppress 
apoptosis (Meyskens, Farmer et al. 2004). 
(a). The progression from melanocytes to melanoma  
 
Figure 6: Depicted a typical nevus and a nevus–associated melanoma.  
Source:http://www.ncbi.nlm.nih.gov/pubmed/?term=The+Morphologic+Universe+of+Melanocytic
+Nevi 
Melanoma can develop de novo or in a pre-existing nevus and tumor risk increases with 
size and cellularity of the nevus. A melanocytic nevus and a nevus derived melanoma 
are shown in Figure 6. Melanocytic nevi are benign neoplasms or hamartomas, 
composed of melanocytes that constitutively colonize in the epidermis. They categorized 
Review of literature 
 
- 19 - 
 
namely into congenital nevi – showing up at birth or within the first few months of life – 
and acquired nevi – arises during an individual’s life time (Krengel, Hauschild et al. 2006; 
Zalaudek, Manzo et al. 2009). 
Melanoma progression from normal melanocytes involves a series of steps as presented 
in Figure 7. About 20–30% of melanomas are thought to arise in association with a 
nevus precursor. In a first step, the proliferation and aggregation of melanocytes into 
nests occurs, leading to nevus generation. The next step comprises progression from 
nevus to melanoma and cells grow into the dermis with physical access to lymphatics 
and blood vessels. In a final step, in metastatic melanoma, tumor cells have spread from 
the primary site and established foci of disease at distant sites [reviewed in (Damsky, 
Rosenbaum et al. 2010)]. 
 
Figure 7: Melanoma progression from melanocytes. Melanoma can develop either from a pre-
existing melanocytic nevus (mole) (25%) or de novo (65%).  
Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756353/ 
 
Furthermore, melanoma develops due to mutations in genes involved in the MAPK 
pathway, which is one of the most important pathways in melanoma tumor development. 
Important oncogenes in this pathway are BRAF, NRAS, HRAS, GNAQ, GNA11 and KIT 
and specific mutations in any of these genes lead to different subtypes of benign and 
malignant melanoma [reviewed in (Fecher, Amaravadi et al. 2008; Yajima, Kumasaka et 
al. 2012)]. p53, which is essential for the protection of DNA against damage is rarely 
mutated early in melanoma, could be one of several adaptations to permit survival of 
cells responsible for generating sun–protective pigment (Eller, Maeda et al. 1997). 
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Except KIT mutations, all of the above–mentioned mutations can also be found in 
melanocytic nevi and in common nevi. For instance, BRAF and NRAS mutations are 
present in 60–87.5% and 20%, respectively of all nevi (Bastian 2014; Van Engen-van 
Grunsven, Kusters-Vandevelde et al. 2014). The symmetric distribution of the neoplastic 
cells in most nevi, the monotony of their constituent melanocytes, and the presence of 
identifiable mutations in bulk populations of nevus cells suggest that nevi result from the 
clonal expansion of a single cell (Bastian 2014). Furthermore, recent 
immunohistochemistry studies analyzing the BRAF status describe BRAFV600E 
mutations in the majority of neoplastic cells in melanocytic nevi and suggest that BRAF 
mutant nevi are clonal (Busam 2013; Bastian 2014; Van Engen-van Grunsven, Kusters-
Vandevelde et al. 2014). 
Persons with an increased number of moles, dysplastic (also called atypical) nevi, or 
having a family history of the disease are at high risk (Slominski, Wortsman et al. 2001; 
Thompson, Scolyer et al. 2005; Shenenberger 2012). Histopathological analysis of 
hematoxylin and eosin–stained tissue sections and correlation with the clinical context 
remains the gold standard for the diagnosis of melanoma and experienced 
dermatopathologists can make a definitive, reliable, and reproducible distinction (Busam 
2013). The American Joint Committee on Cancer (AJCC) approved a new staging 
system for melanoma, based on factors including tumor thickness, ulceration, mitotic 
rate, and sentinel lymph node status, as well as sex and age of the patients, and tumor 
site (Homsi, Kashani-Sabet et al. 2005). 
Non-cutaneous melanocytes lining the choroidal layer of the eye, the respiratory, 
gastrointestinal, and genitourinary mucosal surfaces, or the meninges can occasionally 
also undergo malignant transformation, and develop melanoma, albeit at a low 
frequency (Tsao, Chin et al. 2012). However, comparative studies are suggesting a 
better prognosis for nevus-associated melanoma (Lin, Luo et al. 2015).   
Summing up, melanoma can develop from de novo or in pre-existing melanocytic nevi. 
The prognosis of advanced melanomas is still challenging, although thin melanomas 
have an excellent prognosis, there is great need for the identification of additional 
therapeutics targets. 
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In view of all these facts, I endeavor to investigate the involvement of LASP1 in 
melanogenesis and to study how the existence of LASP1 reflects on human melanoma 
cancer. Immunohistochemical slides with dermal tissues, kindly provided from the 
Department of Dermatology, University Hospital Würzburg, Würzburg, Germany were 
analyzed for LASP1 expression pattern. LASP1 protein expression in cultured normal 
human epidermal melanocyte (NHEM) and in various melanoma cell lines were analysed 
by Western blotting and the subcellular localization of the proteins was examined by 
immunofluorescence. Knockdown as well as melanosome isolation experiments were 
carried out to further scrutinize the function of LASP1 in melanocytes. Additionally, cell 
based assays were performed to examine LASP1 involvement in cell proliferation, 
adhesion and migration.  
In the following sections of this dissertation the experimental methods and results 
obtained are discussed in detail.  
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II. CHAPTER 
MATERIALS AND EXPERIMENTAL PROCEDURES 
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1. List of reagents and equipments 
Table 1: List of cell culture reagents  
Reagents Catalogue Number Manufacturer 
Cholera toxin C8052 Sigma–Aldrich, St. Louis, MO, 
USA 
DPBS 14190 – 094 Gibco® Life Technologies 
GmbH, Darmstadt, Germany 
FCS 10270 – 109 Gibco® Life Technologies 
GmbH, Darmstadt, Germany 
IBMX I5879 Sigma–Aldrich, St. Louis, MO, 
USA 
ITS BD 354351 Sigma–Aldrich, St. Louis, MO, 
USA 
Nutrient Mixture F–10 
Ham 
N6908 Sigma–Aldrich, St. Louis, MO, 
USA 
Penicillin/streptomycin P0781 Sigma–Aldrich, St. Louis, MO, 
USA 
RPMI 61870 – 010 Gibco® Life Technologies 
GmbH, Darmstadt, Germany 
TPA P8139 Sigma–Aldrich, St. Louis, MO, 
USA 
Trypsin–EDTA T3924 Sigma–Aldrich, St. Louis, MO, 
USA 
 
Table 2: List of chemicals  
Reagents Catalogue Number Manufacturer 
Acetic acid 33209 Sigma–Aldrich, St. Louis, MO, 
USA 
Ampicillin A9393 Sigma–Aldrich, St. Louis, MO, 
USA 
APS 21, 558–9 Sigma–Aldrich, St. Louis, MO, 
USA 
Bromophenol blue B – 0126 Sigma–Aldrich, St. Louis, MO, 
USA 
BSA A2153– Sigma–Aldrich, St. Louis, MO, 
USA 
Collagen C9791 Sigma–Aldrich, St. Louis, MO, 
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USA 
Complete mini protease 
inhibitors 
11 836 153 001 Roche, Basel, Switzerland 
Coomassie brilliant blue 
R 
B7920 Sigma–Aldrich, St. Louis, MO, 
USA 
Crystal violet C0775 Sigma–Aldrich, St. Louis, MO, 
USA 
DAPI D9564 Sigma–Aldrich, St. Louis, MO, 
USA 
DMSO D2650 Sigma–Aldrich, St. Louis, MO, 
USA 
Ethanol 32205 Sigma–Aldrich, St. Louis, MO, 
USA 
Fibronectin F4759 Sigma–Aldrich, St. Louis, MO, 
USA 
Forskolin 1099 BIOZOL Diagnostics, 
Eching, Germany 
Glycerol 3783.2 Carl Roth GmbH & Co. KG, 
Karlsruhe, Germany 
Glycine A3707 Sigma–Aldrich, St. Louis, MO, 
USA 
Goat serum G9023 Sigma–Aldrich, St. Louis, MO, 
USA 
H2O2 H1009 Sigma–Aldrich, St. Louis, MO, 
USA 
HCl HC309594 Merck Millipore, Darmstadt, 
Germany 
HEPES H – 7006 Sigma–Aldrich, St. Louis, MO, 
USA 
IPTG I6758 Sigma–Aldrich, St. Louis, MO, 
USA 
Luminol sodium salt A4685 Sigma–Aldrich, St. Louis, MO, 
USA 
Metafectene T020 – 1.0 Biontex Laboratories GmbH, 
Munich, Germany 
Methanol 322.13 Merck Millipore, Darmstadt, 
Germany 
Mowiol 4–88 0713.1 Carl Roth GmbH & Co. KG, 
Karlsruhe, Germany 
NAOH solution  HC273287 Merck Millipore, Darmstadt, 
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Germany 
Non-fat Dry milk 170 – 6404 Bio–Rad Laboratories GmbH, 
Munich, Germany 
Page ruler protein 
marker 
P – 26616 Thermo Scientific, Rockford, 
IL, USA  
p–Coumaric acid C9008 Sigma–Aldrich, St. Louis, MO, 
USA 
PFA P – 6148 Sigma–Aldrich, St. Louis, MO, 
USA 
Ponceau S P3504 Sigma–Aldrich, St. Louis, MO, 
USA 
Rotiphorese® GEL 30 
(37.5:1) Acrylamide A. 
Bisacrylamide stock 
solution 
3029.1 Carl Roth GmbH & Co. KG, 
Karlsruhe, Germany 
SDS L3771 Sigma–Aldrich, St. Louis, MO, 
USA 
Sepharose beads 71024800 GE Healthcare Bio Sciences, 
Uppsala, Sweden  
Sodium bicarbonate S5761 Sigma–Aldrich, St. Louis, MO, 
USA 
Sodium chloride 31434 Sigma–Aldrich, St. Louis, MO, 
USA 
Sodium hydroxide  30620 Sigma–Aldrich, St. Louis, MO, 
USA 
Sodium phosphate S0751 Sigma–Aldrich, St. Louis, MO, 
USA 
Sucrose S0389 Sigma–Aldrich, St. Louis, MO, 
USA 
Synthetic melanin M8631 Sigma–Aldrich, St. Louis, MO, 
USA 
TEMED T9281 Sigma–Aldrich, St. Louis, MO, 
USA 
Tris Buffer grade A1379 AppliChem GmbH, Darmstadt, 
Germany 
Triton X–100 X – 100 Sigma–Aldrich, St. Louis, MO, 
USA 
Trypan blue T8154 Sigma–Aldrich, St. Louis, MO, 
USA 
Tween–20 P1379 Sigma–Aldrich, St. Louis, MO, 
USA 
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β–mercaptoethanol M6250 Sigma–Aldrich, St. Louis, MO, 
USA 
  
Table 3: List of apparatus and instruments 
Instruments Model  Number Manufacturer 
Automatic flake ice machine AF 100 Scotsman Ice Systems,  
Milan – Italy 
Class II Type A2Biosafety 
Cabinet 
SterilGARD® e3 The Baker Company, 
Sanford, Maine  USA 
Electronic balance 1801 Sartorius AG, Göttingen, 
Germany 
Fedegari Steam sterilizer 22657 Integra Biosciences GmbH, 
Fernwald, Germany 
Gel dryer 583 Bio–Rad Laboratories 
GmbH, Munich Germany 
Haemocytometer ZK13 A. Hartenstein,  Society for 
laboratory and medical 
mbH, Würzburg, Germany 
Microplate reader VMAX Molecular Devices, 
Sunnyvale, USA 
pH meter PHM82 Radiometer Analytical, 
Lyon, France 
PowerPac™ HC Power Supply 164–5052 Bio–Rad Laboratories 
GmbH, Munich, Germany 
ScepeterTM  handheld 
automated cell counter  
PHCC00000 Millipore corporation, 
Billerica, MA, USA 
SDS-PAGE electrophoretic 
apparatus 
165–3189 Bio–Rad Laboratories 
GmbH, Munich, Germany 
Sonicator Sonifier 250–102C Branson Ultrasonics, 
Danbury, CT, USA 
Stirrer/hot plate PC–420D Corning Incorporated, 
 NY, USA 
Test tube shaker  
Vibro Shaker 
L46  
V427 
A. Hartenstein,  Society for 
laboratory and medical 
mbH, Würzburg, Germany 
ThermoMixer® compact 5350 Eppendorf Biotech 
Company, Hamburg, 
Germany 
Trans–Blot® Turbo™ Blotting M1703910 Bio–Rad Laboratories 
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System GmbH, Munich, Germany 
UV/visible spectrophotometer Ultra Spec 2000 Amersham Pharmacia 
Biotech Inc., Piscataway, 
USA 
Vacuum Pump Systems 04943239 KNF Neuberger Inc., 
Trenton, USA 
Vortex–Genie  K–550–GE Bender & Hobein AG, 
Zurich, Switzerland 
Wallac 1420 VICTOR 2™ plate 
reader 
1420–018 Perkin Elmer, Baesweiler 
Germany 
Water bath GFL 1083 Gesellschaft für 
Labortechnik GmbH, 
Willich, Germany 
X–OMAT X–Ray Film 
Processor 
RT–KP–M35A Eastman Kodak Company, 
Rochester, N.Y, USA 
List of Incubators 
CERTOMAT® R Benchtop 
Shaker 
CERTOMAT ® H Incubation 
Hood  
BBI–886 3024 
BBI–886 3202 
B. Braun Melsungen AG, 
Tuttlingen, Germany 
CO2 incubator  336 Labor–Technik–Göttingen, 
Rosdorf, Germany 
List of centrifuges 
Bench top centrifuge Universal 320R Hettich Lab Technology 
GmbH, Tuttlingen, 
Germany 
PicofugeTM HF 120 Stratagene, United States 
Refrigerated microcentrifuge 5417R Eppendorf Biotech 
Company, Hamburg, 
Germany 
Super speed centrifuge Sorvall RC–5B Du Pont Instruments, 
Newtown, CT, USA 
Ultra centrifuge L 80 Beckman coulter GmbH, 
Krefeld, Germany 
List of  Microscopes 
Fluorescent microscope Axioskop Zeiss, Oberkochen, 
Germany 
Fluorescent Microscope BZ 9000 Keyence, Osaka, Japan 
Inverted microscope Axiovert 25 Zeiss, Oberkochen, 
Germany 
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List of pipettes 
Single channel pipettes 
 
0.0 – 2.0 µl 
0.5 – 10.0 µl 
2.0 – 20.0 µl 
20 – 200.0 µl 
1000 µl 
Gilson, Inc., Middleton, 
Wisconsin 
Multichannel pipettes 
Multipette® Plus 
3122000051 
022260201 
Eppendorf Biotech 
Company, Hamburg, 
Germany 
Pasteur pipettes 202303 A. Hartenstein,  Society for 
laboratory and medical 
mbH, Würzburg, Germany 
Serological Pipettes 5.0  ml 
10.0 ml 
25.0 ml 
Greiner Bio–One GmbH, 
Frickenhausen, Germany 
Accu–jet® pro pipette 
Controller 
26330 BrandTech® Scientific, 
Essex, CT, USA 
Pipette stand F161401 Gilson, Inc., Middleton, 
Wisconsin 
List of refrigerators and freezers 
4oC Kirch Gmbh, Offenberg, Germany 
–20oC Liebherr MediLine, Newport Pagnell, MK, UK 
–80oC  –860C ULT Thermo Scientific Inc., 
Waltham, MA USA 
Glass homogeniser HOG3 A. Hartenstein,  Society for 
laboratory and medical 
mbH, Würzburg, Germany 
  
Table 4: List of disposables  
Items Item Numbers Manufactures 
Combitips advanced® 
 
2.5 ml – 0030 089.448 
5.0 ml – 0030 089.456 
Eppendorf Biotech 
Company, Hamburg, 
Germany 
Biosphere® Pipette 
Tips  
0–10 µl 
20–200 µl 
100–1000 µl 
Sarstedt AG & Co,  
Nümbrecht, Germany 
X–50 scepter sensors 
(60µM) 
PHCC60050 Merck Chemicals GmbH, 
Schwalbach am Taunus, 
Germany 
Glass slides Duran Group GmbH, Wertheim/Main, Germany 
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X–ray film 47410.19236 Fujifilm corporation,  
Tokyo, Japan 
Nitrocellulose 
membrane 
10401 196 GE Healthcare Bio 
Sciences, Uppsala, 
Sweden 
Cover slips 24mm 
Cell scraper 
Whatsmann filter paper
   
DKR5 
C25B 
F859 
A. Hartenstein Society for 
laboratory and medical 
mbH, Würzburg, Germany 
List of cell culture plates and flasks 
Tissue culture plates  
 
 
 
Cell suspension plate 
White Lumitrac 200 
plate 
Cell culture flasks 
 
6 well   – 657 160 
12 well – 665 180 
48 well – 677 180 
96 well – 655 180 
48 well – 677 102 
96 well – 655086 
T 25   – 690 175 
T75    – 658 170 
T150  – 660 160 
Greiner Bio–One GmbH 
Frickenhausen, Germany 
Transwell® Inserts 3458 Corning Incorporated,  
NY, USA 
Cryovials 710522 Biozym Scientific GmbH, 
Oldendorf, Germany 
List of tubes 
Microcentrifuge tubes 1.5 ml – 
2.0 ml – 
Eppendorf Biotech 
Company, Hamburg, 
Germany 
Falcon tubes 15.0ml 
50.0 ml 
Greiner Bio–One GmbH, 
Frickenhausen, Germany 
14 ml PP tubes 187 261 Greiner Bio–One GmbH, 
Frickenhausen, Germany 
Ultra centrifuge tubes 344057 Beckman Instruments,  
CA, U.S.A 
List of miscellaneous items 
SensiCare® Ice gloves 486802 Medline Industries, Inc., 
Mundelein, Illinois, USA 
Terralin®  Z11091 Schülke & Mayr GmbH, 
Norderstedt, Germany 
Microliter™ syringe MH 03 Hamilton Bonaduz AG, 
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Bonaduz, GR, Switzerland 
Omnican® Insulin 
syringe (30G X ½’’)  
U – 40 B. Braun Melsungen AG, 
Tuttlingen, Germany 
Filtropur S  0.45 µm 
syringe filter 
83.1826 Sarstedt AG & Co,  
Nümbrecht, Germany 
Disposable syringes 2 ml   – 300928 
5 ml   – 309050 
10 ml – 309110 
Becton Dickinson, New 
Jersey, USA 
Aqua Ad Iniectabilia 3170/1 DeltaSelect GmbH, 
Munich, Germany 
Surgical disposable 
scalpel  
2019–10 B. Braun Melsungen AG, 
Tuttlingen, Germany 
Hand held counters  
Table stopwatch  
Digital timer  
Parafilm® M  
Test tube stand  
KM13 
KM14 
KM10 
PF10 
GR07; GRE3; GR25 
A. Hartenstein Society for 
laboratory and medical 
mbH, Würzburg, Germany 
Scanner CanoScan 5200F Canon, Tokyo, Japan,  
 
Table 5: List of antibodies, origin, and dilutions  
List of primary antibodies 
Antibody Type Purpose/ 
Dilution 
Cata. No./ 
Conc. 
Manufacturer 
Actin 
(I–19) 
Rabbit 
Polyclonal 
WB (1:5000)  sc–1616–R 
200 µg/ml 
Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
Dynamin  
(E–11) 
Mouse 
Monoclonal 
WB (1:200) 
IF (1:20) 
sc–17807 
200 µg/ml 
Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
GAPDH 
(V–18) 
Goat  
Polyclonal 
WB (1:2000) sc–20357 
200 µg/ml 
Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
Histone 
H2B 
(N–20) 
Rabbit 
Polyclonal 
WB (1:2000) sc–8650 
200 µg/ml 
Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
Lamin A/C 
(N–18) 
Rabbit 
Polyclonal 
WB (1:2000) sc–3216 
200 µg/ml 
Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
LASP1  Rabbit WB (1:5000) 380 µg/ml ImmunoGlobe GmbH, 
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Polyclonal IF (1:250) 1.6 mg/ml Himmelstadt, 
Germany 
PKA Rabbit 
Polyclonal 
WB (Lohmann, Walter et al. 1980) 
pLASP1 Rabbit 
Polyclonal 
WB (1:5000) 55 µg/ml ImmunoGlobe GmbH, 
Himmelstadt, 
Germany 
TRP1 
(H–90) 
Rabbit 
Polyclonal 
WB (1:200) sc–25543  
200 µg/ml 
Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
Tyrosinase 
(T311) 
Mouse  
Monoclonal 
WB (1:200) 
IF (1:20) 
sc–20035 
200 µg/ml 
Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
Tyrosinase 
 
Rabbit 
Polyclonal 
 
IF (1:20) 
ab58450 
 1 mg/ml 
Abcam, Biotech 
company, Cambridge, 
United Kingdom 
ZO2 Rabbit 
Polyclonal 
WB (1:1000) 2847S 
100 µl 
Cell Signaling, 
Beverly,  
U.S.A 
Zyxin Mouse 
Monoclonal 
WB (1:2000) 307 011 
100 µg 
Synaptic Systems, 
Goettingen, Germany 
Rab27A Mouse 
Monoclonal 
WB (1:200) MABN446 
100 µg 
EMD Millipore 
Bioscience, 
Billerica, MA, USA 
BIP Rabbit 
Polyclonal 
WB (1:1000) 3183 
100 µl 
Cell Signaling, 
Beverly,U.S.A 
List of secondary antibodies 
Cyanine 3  anti–
rabbit 
IF (1:250) 111–165–045 
1.5 mg/ml 
Dianova, Hamburg, 
Germany 
Cyanine 2 anti–
mouse 
IF (1:250) 115–225–146 
1.5 mg/ml 
Dianova, Hamburg, 
Germany 
Goat anti–mouse 
HRP conjugate 
WB 
(1:5000) 
170–6516 
2ml 
Bio–Rad Laboratories 
GmbH, Munich, 
Germany 
Goat anti–rabbit 
HRP conjugate 
WB 
(1:5000) 
170–6515 
2ml 
Bio–Rad Laboratories 
GmbH, Munich, 
Germany 
Donkey anti–goat 
HRP conjugate 
WB 
(1:5000) 
sc–2020 
200 µg/0.5 ml 
Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
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Table 6: List of siRNA  
siRNA Target sequence Manufactures 
Control siRNA 5’AATTCTCCGAACGTGTCACGT–3‘ Qiagen company 
Hilden, Germany 
LASP1 siRNA 5´–AAG CAT GCT TCC ATT GCG 
AGA –3` 
Qiagen company 
Hilden, Germany 
 
Table 7: Plasmid and manufacturer 
Plasmid Catalogue No. Manufacture 
pGEX – 4T – 1 27–4580–01 GE Healthcare Bio Sciences, 
Uppsala, Sweden 
 
Table 8: List of kits  
Kits Catalogue No. Manufactures 
Pierce™ BCA Protein Assay Kit 23223 Pierce Biotechnology, 
Rockford, IL, USA 
CellTiter–Glo® Luminescent Cell 
Viability Assay kit 
G7571 Promega Corporation, 
Madison, WI, USA 
NE – PER Nuclear and 
Cytoplasmic Extraction Reagents 
78833 Pierce Biotechnology, 
Rockford,  lL, USA 
 
Table 9: List of softwares, websites and databases 
Wallac software Wallac 1420 explorer 
Elisa software Softmax version 3.32 
BZ 9000 software BZ II viewer 
Adobe photoshop Photoshop CS2 
Microsoft office Office 2013 
Graph pad http://www.graphpad.com/ 
Statistical test calculator http://www.socscistatistics.com/Default.aspx 
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2. Formulations and preparations of Reagents 
ECL Home–made  
Stock solutions  
Solution A                          : 100 ml 0.1 M Tris/HCl (pH 8.6) and 25 mg 
luminol (stored at 4oC). 
Solution B                          : 11 mg para–hydroxy coumarin acid in 10 ml   
DMSO (stored at  room temperature). 
Solution C   :   H2O2 (30%) (Stored at 4
oC). 
Working solution –  The above listed solutions were mixed in a proportion – 3 ml reagent 
A +  300 µl reagent B + 0.9 µl H2O2. 
Crystal violet (1%, 50 ml) 
 Crystal violet   : 0.5 g 
 Ethyl alcohol   : 2% 
Working solution – 0.5 g of crystal violet was dissolved in 50 ml of 2% ethyl alcohol. The 
solution was filtered using 0.45 µm filter before use.   
Transfer buffer for tank blotting  
Tris–glycine buffer (Towbin buffer) – (1X, 10 L) 
(A) 25 mM TRIS (Base)  : 30 g 
192 mM glycine  : 144 g 
NaOH pellet   : 56 g 
(B) 20% methanol  : 2 L 
Working solution – All the above listed reagents (A) were dissolved in distilled water and 
pH was adjusted to 10.0. To this solution, 2 L of methanol was added and made up to 10 
L. Transfer buffer was stored in cold room.  
Collagen  
 Collagen   : 1 mg 
Acetic acid   : 0.1 M  
Stock Solution – 1 mg of collagen was dissolved in 1 ml of 0.1 M acetic acid, mixed 2–3 
hr in magnetic stirrer and was stored at 4oC. 
Working Solution (50 µg / mL) – 1 ml of stock solution was mixed with 9 ml of ice cold 
PBS.  
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Blocking medium (3%, 100 ml) 
3% non–fat Dry milk  : 3 g 
Working solution – 3 g of milk powder was dissolved in 100 ml of 1X TBST and the 
solution was stored at 4oC.   
Ammonium persulphate (10%, 10 ml) 
 APS    : 1 g 
Working solution – 1 g of APS was dissolved in 10 ml of distilled water and stored at 
4oC.  
Ampicillin (0.1%, 10 ml) 
 0.1% ampicillin  : 1 g 
 50% ethyl alcohol  : 10 ml 
Working solution – 1 g of ampicillin was dissolved in 10 ml of 50% ethyl alcohol. The 
solution was stored at –20oC.  
Staining and destaining solution 
Coomassie brilliant Blue 
Coomassie brilliant blue : 0.8 g 
Isopropanol absolute  : 200 ml 
Acetic acid   : 200 ml 
Working solution – All the above listed reagents were dissolved in distilled water and 
made up to 2 L. The solution was filtered before use.  
Destaining solution 
Acetic acid   : 10%  
Ethyl alcohol   : 10%  
Working solution – The two solutions were mixed together and made up to 1 L and kept 
at room temperature.  
IPTG (1 M) 
 IPTG    :  238 mg  
Working solution – 2.38 g of IPTG was dissolved in 10 ml of distilled water and stored at 
–20oC. 
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Sodium Dodecyl Sulphate (10%, 100 ml)  
 SDS    :  10 g 
Working solution –10 g of SDS was dissolved in 50 ml deionized water with gentle 
stirring and brought to 100 ml. Stored at room temperature. 
Luria Broth (LB medium) (1 L) 
(A) Trytone    : 10 g 
Yeast extract   : 5 g 
NaCl    : 5 g  
(B) Ampicillin     
Stock solution – All the components (A) were mixed in 1 L of deionized water and 
sterilized by autoclaving at 15 psi, from 121–124°C for 15 min. Stored at room 
temperature.  
Working solution – To the above solution ampicillin was added.  
Ponceau S solution (0.5%, 100 ml) 
Ponceau S   : 0.5 g 
Acetic acid   : 10% 
Working solution – 0.5 g of Ponceau S was dissolved in 100 ml 10% acetic acid and 
stored at room temperature.  
Laemmli sample buffer (3X, 100 ml) 
(A) Tris/HCl (pH–6.7)  : 200 mM 
SDS    : 6 g 
 Glycerin   : 15% 
Bromophenol blue  : 3 mg  
(B) β–Mercaptoethanol  : 10% 
Stock solution – All reagents (A) were dissolved in 100 ml of distilled water and stored at 
room temperature.  
Working solution – To 9 ml of stock solution, 1 ml of β–mercaptoethanol was added. The 
solutions were kept at room temperature.  
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Hypotonic buffer (1X, pH 8.1, 100 ml) 
(A) HEPES   : 10 mM  
KCl     : 10 mM  
EDTA    : 1.5 mM  
Sucrose   : 200 mM  
(B) Complete Mini proteases : one tablet/10 ml 
Stock solution – All the above listed reagents (A) were dissolved in 70 ml of deionized 
water, pH was adjusted to 8.1 and the solution was made up to 100 ml. Stored at 4oC.  
Working solution – To 10 ml of the solution, one tablet of complete mini proteases was 
added.  
E.coli lysis buffer (1X, pH 8.0, 100 ml) 
(A) Tris/HCl (pH 8.0)  : 50 mM   
EDTA    : 1 mM  
NaCl    : 100 mM  
(B) Triton X–100   :  0.1%   
 Complete Mini proteases : one tablet/10 ml 
Stock solution – All the above listed reagents (A) were added in 70 ml of deionized 
water, pH was adjusted to 8.1. To this solution, 0.1% triton X–100 was added and made 
up to 50 ml. Stored at 4oC.  
Working solution – To 10 ml of the solution, one tablet of complete mini proteases was 
added. 
Tris–buffered Saline (10X, pH7.5, 1 L) 
(A) 100 mM Tris   : 100 mM 
1.5 mM NaCl   : 1.5 mM 
(B) 0.1% Tween 20  : 1 ml 
Stock solution – The reagents (A) were dissolved in 500 ml of distilled water and pH was 
adjusted to 7.5, made up to 1 L. Stored at room temperature.  
Working solution (1X TBS–T) – To 100 ml of the stock solution, 900 ml of distilled water 
was added. 
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SDS–PAGE running buffer (10X, pH 8.9, 1 L) 
(A) 250 mM TRIS (Base)  : 120 g 
192 mM glycine  : 576 g 
1% SDS   : 40 g 
Stock solution – All reagents were dissolved in distilled water and made up to 4 L. The 
buffer was stored at room temperature. 
Working solution (1X, 1l) – To 100 ml of the stock solution, 900 ml of distilled water was 
added and used for PAGE. 
Bovine serum albumin (1%, 50 ml) 
 1% BSA   : 0.5 g 
 PBS    : 50 ml 
Working solution – 0.5 g of BSA was dissolved in 50 ml of PBS by vortexing. The 
solution was then filtered in 0.45 µM filter and stored at 4oC.  
Sodium hydroxide (1N, 100 ml) 
 NaOH    : 4 g 
 DMSO    : 10 ml 
Working solution – 4 g of NaOH pellets were dissolved in 10 ml of DMSO solution. 
HEPES buffer (10 mM, 250 ml) 
 HEPES   : 0.59 g 
Working solution – 0.59 g of HEPES was added in 100 ml of distilled water and pH was 
adjusted to 7.0, and then made up to 250 ml. Stored at 4oC.  
Paraformaldehyde (4%) 
 PFA    : 4 g 
 PBS    : 100 ml 
Working solution – 4 g of PFA was added to 100 ml of PBS, heated to 70oC and the 
solution was stored at –20oC.  
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Western blotting Gel preparation  
(A) Resolving gel 
Components   15%  13%  10%  9%  
Deionized H2O  14.45 ml 17.50 ml 21.15 ml 11.20 ml 
30 % Acrylamide Solution 20.0 ml 17.30 ml 13.30 ml  6.0 ml 
Tris Buffer (3.0 M, pH 8.9) 5.0 ml  5.0 ml  5.0 ml              5.0 ml 
10% SDS   0.4 ml  0.4 ml  0.4 ml              0.40 ml 
10% APS   0.4 ml  0.4 ml  0.4 ml              0.40 ml 
TEMED   20.0 µl  20.0 µl  20.0 µl              20.0 µl 
 
(B) Stacking gel 
Components   Volume   
Deionized H2O   14.4 ml  
30% Acrylamide Solution  2.8 ml   
Tris Buffer (0.5M, pH 6.7)  2.6 ml   
10% SDS    0.2 ml   
10% APS    0.8 ml   
TEMED    20 µl  
 
List of culture vessels and amount of medium used 
Culture vessels Area     Medium used 
48 well   1.0 cm2  250 µl 
12 well   3.9 cm2  1.0 ml 
6well   9.6 cm2  2.0 ml 
T25   25 cm2   5.0 ml 
T75   75 cm2   15.0 ml 
T150   150 cm2  30.0 ml 
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Volume of trypsin and medium used for trypsinization 
           Culture vessels      Trypsin used     Medium used 
6 well    200 µl   2 ml 
T25    1 ml   3 ml 
T75    2 ml   3 ml 
T150    4 ml   6 ml 
Cell freezing medium (6 ml) 
Cell culture medium  : 3.4 ml  
FCS    : 2.0 ml 
DMSO    : 0.6 ml  
Working solution – All the components were mixed in a 15 ml greiner.  
 
Composition of Sucrose Step Gradient solutions 
Composition of step solution  
Step concentration 2 M sucrose stock  H2O (ml) 1 M HEPES (µl) 
(M)    solution (ml)     
 
2.0      20    –     – 
1.8     18   1.8   200 
1.6     16   3.8   200 
1.5     15   4.8   200 
1.4     14   5.8   200 
1.2     12   7.8   200 
1.0     10   9.8   200 
0.25    2.5   17.3   200 
Working solution – Complete mini proteases was added to the above solutions and step 
gradient was prepared in ultracentrifuge tubes.  
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3. Methodology 
A. Cell culture methods 
a. Growth medium and cell culture conditions 
RPMI and HAM’s nutrient medium containing L–glutamine were used for cell culturing. 
RPMI medium was supplemented with 10% fetal calf serum (FCS) and 1% 
penicillin/streptomycin (100 U ml−1). Nutrient mixture F–10 HAM's media was 
supplemented with 20% FCS, ITS premix (a mixture of recombinant human insulin, 
human transferrin, and sodium selenite), (3–Isobutyl–1–methylxanthine) IBMX, and 
cholera toxin. 12–O–tetradecanoylphorbol–13–acetate (TPA) was freshly added to the 
medium. The cells were grown at 37oC and 5% CO2 incubator. 
b. Cell lines 
Human melanoma cell lines: LOXIMVI, M14, M19, MaMel2, MDAMB435, SkMel2, 
SkMel5, UACC62 and UACC257 and breast cancer cell line: MDAMB231 were grown in 
RPMI growth medium. Normal human epidermal melanocyte (NHEM) was cultured in 
HAM's F10 nutrient medium. 
c. Recovery of cryopreserved cells 
Cell culture flasks and tubes were prepared with the recommended volume of the 
appropriate complete growth medium as mentioned in the previous section. The 
cryovials containing cells were thawed by gentle agitation in a water bath at 37°C and 
decontaminated by 70% ethanol. The cells were then transferred to the tubes containing 
medium and centrifuged at 160 x g for removing the cryoprotectant agent, dimethyl 
sulfoxide (DMSO). Supernatant was discarded and the cells were re-suspended in 1 ml 
of culture medium. The cell suspension was then transferred into the culture vessel 
containing medium and mixed thoroughly by gentle rocking. 
d. Monolayer sub-culturing 
All the solutions (trypsin–EDTA solution, Dulbecco’s Phosphate Buffered Saline (DPBS) 
without calcium or magnesium, and complete growth medium) were pre-warmed at 37oC 
in a water bath. At 70–90% confluence, cells were subcultured up to 4–6 passages.  
Medium from the culture flask was removed and the monolayer was rinsed once with 
DPBS. 200 µl–4 ml (depending on the size of the culture vessels) of the trypsin EDTA 
solutions was added and incubated in the CO2 incubator for 2–5 min. The cell 
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dissociation was controlled under microscope. To the detached cells, 2–6 ml of culture 
medium was added to inactivate the trypsin and then centrifuged at 160 x g.  
Supernatant was discarded and the cells were resuspended in 1 ml of the culture 
medium. Depending on the cell growth, cells were diluted and transferred to flasks and 
mix thoroughly by gentle rocking.  
e. Cryopreservation procedure 
Cell freezing medium consisting of complete growth medium, 10% FCS and 5% DMSO 
was prepared. The cells were collected by centrifugation at 160 x g and resuspended 
them in the freezing medium (6 ml medium/90% fully confluent cells in T75 flask). 
Approximately 1.8 ml of the cell suspension was added to cryovials labelled with the 
name of the cell line and the date. The vials were then kept at –20oC for 2–3 days and 
later transferred to liquid nitrogen tank.  
B. Immunohistochemistry 
Immunohistochemistry slides of tissue samples stained for LASP1 and MART1 were 
kindly provided from the Department of Dermatology, University Hospital Würzburg. The 
specimens include normal skin, 29 nevi, 58 malignant melanoma and 20 metastases 
samples with confirmed histological diagnosis. The samples were later photographed. 
Evaluation of immunohistochemical LASP1 staining and LASP1 – IRS 
Immunohistological samples were evaluated by two independent scientists to define the 
percentage of LASP1 positive cells, and to distinguish nuclear and cytosolic 
immunoreactivity. Scoring of cytosolic LASP1 expression was carried out in analogy to 
the scoring of the hormone receptor Immunoreactive Score (IRS), ranging from 0–12. 
The immunohistochemical staining was scored as described below: the intensity of 
staining was scored as 0, 1, 2 or 3 indicating absent, weak, moderate or strong 
expression, respectively. The percentages of positive cells were scored as 0 for 0–19%, 
1 for 20–39%, 2 for 40–59%, 3 for 60–79% and 4 for 80–100%. The multiplication of 
these two scores was used to identify the LASP1 expression level. For statistical 
discrimination, samples scored with cytosolic LASP1–IRS <3 were classified as LASP1–
negative and those with LASP1–IRS >2 as LASP1–positive. Nuclear LASP1 positivity 
was scored by determining the percentage of positive nuclei regardless of cytosolic 
LASP1 immunoreactivity. Samples were considered to be nuclear–positive if 10% or 
more cells showed nuclear LASP1 staining.  
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C. SDS–PAGE and Western blotting 
a. SDS–PAGE  
For Western blot analysis, cells were counted, washed once in 1X PBS and lysed in 
appropriate volume of Laemmli sample buffer. The total cellular proteins were resolved 
by 9–13% polyacrylamide gel. SDS–PAGE gel was prepared in a gel–molding cassette 
according to the quantities of reagents listed in the above section. The gel plates were 
then clamped to the electrophoresis chamber, filled with 1X electrode buffer and 
electrophoresis was done by giving a DC supply of 70 V for running through stacking gel 
and 120 V for resolving gel at room temperature till the dye front reached the bottom.  
b. Western blotting 
The resolved proteins were transferred to nitrocellulose membrane by immunoblotting. 
For blotting, a transfer sandwich was assembled using Scotch–brite pads, gel–blotting 
paper, resolved gel and nitrocellulose membrane presoaked in transfer buffer and were 
transferred for 1 hr at 1.8–2.2 A at 4oC. The membrane was then incubated for 2 min in 
Ponceau S solution for reversible detection of bands and washed in PBS. After blocking 
with 3% non-fat dry milk in TBST for 30 min at room temperature, membrane was 
incubated overnight with specific primary antibodies at 4°C. Followed by washing three 
times with TBST, the blots were incubated with HRP–labelled secondary antibodies for 1 
hr at room temperature. After washing, the protein bands were visualized by 
autoradiography using enhanced chemiluminescence. β–Actin was used as a loading 
control.  
D. p53 status 
p53 status in the cell lines used for experiments was checked in the database 
http://p53.free.fr/Database/Cancer_cell_lines/NCI_60_cell_lines.html and some were 
kindly provided from the Department of Dermatology, University Hospital Würzburg.  
E. siRNA transfection 
Transfections were performed according to the manufacturer’s protocol for suspension 
culture using metafectene® transfection reagent. A siRNA molecule targeting for LASP1 
(5’–AAG CAT GCT TCC ATT GCG AGA –3’) (bases 80–100) and a control siRNA were 
used for transfection. Transfection complex was prepared by incubating a mixture of 12 
µl metafectene and 1.2 µM of siRNA for 15 min. Suspended cells at a density of 1x105 
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cells/ml were seeded and incubated directly with transfection complex. Cells were 
maintained at 37°C under 5 % CO2 atmosphere for 72 hr. 
F. Cell based assays 
a. Proliferation assay 
For proliferation assay, cells transfected with siRNA against LASP1 and control siRNA 
were seeded (1x104 cells/200 μl) in 48 well plates and cultured for 72 hr. The cell viability 
was determined by the CellTiter–Glo® Luminescent Cell Viability Assay according to the 
manufacturer´s instructions. Briefly, a volume of 200 μl of CellTiter–Glo® reagent was 
added and cells were lysed by shaking and incubating for 10 min at room temperature. 
Luminescence signal was measured using Wallac 1420 microplate reader at 590 nm. 
The assay was performed in eight replicates and was independently repeated four times. 
Cell proliferation is expressed as percentage of control cells.  
Cell proliferation was also performed by counting the viable cells using automatic 
handheld cell scepter and by counting using haemocytometer after trypan blue staining. 
Experiments were repeated independently four times. LASP1 depletion was confirmed 
by Western blotting (WB). 
b. Cell adhesion assay 
Cell suspension culture plates were coated with extracellular matrix protein, collagen (50 
µg/ml), incubated for 1.30 hr and blocked with 1% BSA in 1X PBS for 30 min. These 
plates washed in 1X PBS were then used for the assay. 72 hr after transfection, cells 
were counted and seeded on collagen coated plates with a density of 4x104 cells/well 
and allowed to grow at 37°C in a humidified incubator for 4–6 hr (50% adhesion for 
control cells). Non-adherent cells were removed by gentle washing with PBS and the 
wells were refilled with 100 µl of medium. Leftover non-washed off wells containing cells 
were served as 100% control. Adherent cells were counted with CellTiter–Glo® 
Luminescent Cell Viability Assay according to the manufacturer´s instruction. In brief, 
100 µl of the reagent mixture was added and incubated for 10 min and the luminescence 
signal was detected using Wallac microplate reader at 590 nm. Assays were performed 
in six independent experiments each with five replicates. Knockdown of LASP1 was 
verified by WB. 
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c. Transwell migration assay 
Cell migration was performed in a modified Boyden chamber. Prior to the experiments, 
lower surface of the transwell filters (8μm pore size) was coated with a chemo-attractant, 
fibronectin (5 µg/ml) in 1X PBS and incubated for 15 min and the inner filter chambers 
were coated with 100 µl 10% FCS in medium for 30 min. Cells serum–starved overnight 
were trypsinized, counted and re-suspended in serum–free RPMI medium containing 
0.1% BSA at a density of 1.5x106 cells/ml. 500 µl RPMI medium containing 0.1% BSA 
and 10% FCS was added to the lower chamber of each transwell and 100 µl cell 
suspension (1.5x105 cells) was placed in the upper filter chambers and were allow to 
transmigrate through the filter for 4–6 hr (37°C; 5% CO2). The non-migratory cells on the 
upper chamber were removed with a cotton swab, and the cells that migrated through 
the membrane were stained using 1% (w/v) crystal violet in 2% ethanol for 30 sec and 
then rinsed twice in distilled water. The cell-associated crystal violet stains were 
extracted by incubating the membrane for 20 min in 10% acetic acid and measured the 
absorbance at 595 nm, using microplate reader. All samples were prepared in six 
replicates, and the experiment was repeated at least three times. LASP1 knockdown 
was checked by WB. 
G. Immunofluorescence 
For immunofluorescence microscopy, cells were grown to 70–80% confluency on glass 
coverslips. Cells were fixed in 4% (w/v) paraformaldehyde in PBS (10 min), blocked 
using NH4Cl (10 min) and then permeabilized with 0.1% (w/v) Triton X–100 in PBS (10 
min). After each step, cells were gently washed three times using 1X PBS. Cells were 
then blocked for 30 min in 5% goat serum (0.1% (w/v) Triton X–100 in PBS) and 
incubated with primary antibodies for 1 hr. The primary antibodies used were affinity–
purified rabbit polyclonal LASP1 and rabbit polyclonal tyrosinase, in combination with 
either mouse monoclonal dynamin or mouse monoclonal tyrosinase. Followed by 
washing three times in 1X PBS, cells were incubated in Cy3–labeled anti–rabbit and/or 
Cy2–labeled anti-mouse antibodies for another 1 hr. Antibodies dilution are mentioned in 
Table 5. Afterwards, coverslips were washed in 1X PBS, then in water and 
counterstained for nucleus with DAPI. Coverslips were mounted with a drop of mowiol on 
glass slides labeled for staining and cell lines. The glass slides with mounted samples 
were kept at 4oC for further examination. 
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H. Determination of intracellular melanin content 
For intracellular melanin estimation, cells were transfected (control and LASP1) with 
siRNA and seeded at a density of 1×105 cells/ml. 72 hr post transfection, cells were 
harvested, washed once in PBS and lysed in 1N NaOH in 10% DMSO. Cellular melanin 
was dissolved by incubating the homogenate at 80°C for 2 hr and then centrifuged for 5 
min at 500 x g. Absorbance of the supernatant was measured at 405 nm using 
microplate reader. Synthetic melanin diluted in 1N NaOH was used as standard, ranging 
from 0–80 µg/ml. Three determinations were performed in duplicates and the cellular 
melanin content is expressed as percentage.   
I. Expression and purification of GST proteins 
a. Overexpression of proteins in E.coli cells 
Inoculated a small portion of E.coli strain transformed with pGEX–LASP1 recombinant 
plasmid and pGEX control plasmid in 2 ml Luria–Bertani (LB) medium (with ampicillin). 
The inoculum was grown overnight at 37°C with vigorous shaking and thereafter the 
cultures were diluted to 1:100 in LB medium and incubated at 37oC. The optical density 
at 600 nm was checked periodically, setting LB medium as blank until the culture reading 
reached 0.7. Subsequent stimulation with IPTG, the cultures were incubated for another 
3 hr at 37oC and bacterial cells were harvested by centrifugation at 3000 x g at 4°C for 
10 min. The cell pellets frozen at –20°C overnight were re-suspended in ice cold E.coli 
lysis buffer (containing complete mini proteases) and incubated for 10 min on ice. Then 
sonicated at 60% amplitude for 30 sec with an interval of 1 min and allow the solution to 
cool on ice for 5 min. Sonicates were later centrifuged at 20,000 x g at 4°C for 15 min, 
and the supernatants (soluble fraction) were carefully transferred to a clean, pre–chilled 
tube.  
b. Purification of GST proteins using Sepharose 4B beads 
High affinity glutathione sepharose 4B beads were used for purification of the GST–
LASP1 fusion protein and the GST protein. The bottle containing beads were mixed by 
gentle shaking until all the resin was completely in suspension. 20 µl of the beads in 
suspension (50% slurry) was transferred to a new microcentrifuge tube and washed 
three times in ice cold 1X PBS by centrifugation at 500 x g for 30 sec. The supernatant 
containing either the GST–control or LASP1 fusion protein were then mixed to the beads 
and incubated for 1 hr at 4oC. The mixture was centrifuged at 500 x g for 30 sec and 
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beads were re-suspended in 500 µl of 1X PBS and stored at 4oC. From every sample a 
small fraction was stopped in Laemmli lysis buffer for SDS–PAGE. 
c. Analysis of GST–fusion proteins 
10 μl aliquots of each sample were resolved in 9% SDS–PAGE and gels were stained 
with Coomassie brilliant blue at room temperature. After 1 hr, gels were incubated in 
destaining solution for the visualization of the band and were dried later. BSA (0.1–1.0 
mg) was used as standard for checking the concentration of the bound protein.  
J. Pull-down using GST fusion proteins 
MaMel2 cells were harvested, counted and 1x106 cells were re-suspended in 500 µl of 
1X hypotonic buffer (complete mini proteases). Followed by incubation on ice for 30 min, 
cell disruption was done by freeze and thaw in liquid nitrogen and subsequent mechanic 
lysis with a 29 1/2 gauge needle. The resultant homogenate was centrifuged at 20,000 x 
g for 15 min at 4oC and the supernatant was incubated with 50 µl of GST–control and 
GST–LASP1 beads at 4oC on a rotary mixer. After 2 hr, the samples were centrifuged 
and beads were washed once in ice–cold lysis buffer and twice in 1X PBS. The samples 
were analyzed by WB for bound proteins.   
K. Melanosome isolation by sucrose density gradient centrifugation  
Melanosomes were purified by sucrose density gradient ultracentrifugation. Briefly, cells 
were harvested and washed once in 0.25 M sucrose solution by centrifugation at 160 x g 
for 5 min at 4oC. Cells were then homogenized on ice using 20 strokes of a Dounce 
glass: glass homogenizer and centrifuged at 1000 × g for 10 min at 4°C. The cellular 
supernatant containing melanosomes was layered on a discontinuous gradient of 1.0–
2.0 M sucrose solution in 10mM HEPES, pH 7.0 (1.0, 1.2, 1.4, 1.5, 1.6, 1.8, and 2.0 M) 
and centrifuged at 100,000 x g in a Beckman SW28 swinging–bucket rotor for 1 hr at 
4°C. The gradients were performed in two different orientations as illustrated in Figure 8. 
But the reverse sucrose gradient did not work well. Melanosomes that localized at 
various layers of the gradient were carefully collected and analysed by immunoblotting 
using antibodies indicated in figure legends in the result section. 
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Figure 8: Schematic representation of the protocol for differently oriented sucrose density 
gradients. 
L. Preparation of nuclear and cytosolic cell fractions 
Cell lysis and centrifugal isolation of nuclear and cytoplasmic protein fractions was 
carried out using NE PER nuclear and cytoplasmic extraction reagents following the 
manufacturer's instructions. Briefly, cells were starved overnight and treated with 
forskolin (5 µM/ml) for 20 min for phosphorylation. Forskolin–treated, as well as 
untreated cells, were harvested, washed once in PBS and nuclei and cytosol was 
isolated using NE–PER kit. The protein concentration of the samples was estimated 
using BCA reagent and equal protein amount of the fractions was loaded and analysed 
by WB. The purity of the isolated fractions was controlled by GAPDH, lamin A/C or 
histone H2B. 
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A. Melanocyte –  specific function of LASP1 
1. LASP1 protein expression pattern in tissue samples and in different cell lines 
 
The tissue samples were examined by immunohistochemistry with antibodies against 
LASP1 and MART1 in consecutive sections. Cultured normal human epidermal 
melanocytes (NHEMs) and nine melanoma cell lines were analyzed by Western blotting. 
1.1. LASP1 is present in stratum basale of normal skin and is highly expressed in 
melanocytic nevi  
Skin is composed of different layers – epidermis, dermis and hypodermis. The different 
epidermal layers of skin are presented in Figure 9 A. The epidermis is relatively thin and 
the tough outer layer of skin and stratum basale is the deepest of the five epidermal 
layers. A representative human normal skin section immunostained for LASP1 is shown 
in Figure 9 B. LASP1 exhibits a distinct expression in the stratum basale (basal layer) of 
the epidermis of skin.  
 
Figure 9: Human skin. (A) Diagrammatic presentation of the different layers of epidermis. 
Source: http://en.wikipedia.org/wiki/Stratum_basale#/media/File:Skinlayers.png (B) Paraffin 
embedded section of normal skin immunostained for LASP1. LASP1 positively stains the stratum 
basale of epidermis. (Magnification 20X) 
The epidermal basal layer of skin consists of melanocytes, the pigment producing cells, 
and basal keratinocytes. Representative specimens of two consecutive sections of 
normal skin, immunostained for LASP1 and MART1 (a protein antigen present in the 
surface of melanocytes) (Sheffield, Yee et al. 2002; Prieto and Shea 2011) are depicted 
in Figure 10. LASP1 immunostaining is detected in both, basal melanocytes and 
keratinocytes (Figure 10 A). The intermittent staining of MART1 in the basal layer 
represents melanocytes (Figure 10 B). In the dermis, histiocytes (yellow arrow) and 
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blood vessels with vascular smooth muscle cells (red arrow) also exhibit LASP1–
positivity (Figure 10 A). 
 
Figure 10: Consecutive sections of normal skin stained with LASP1 and MART1 
antibodies. (A) LASP1 stained the basal cells in the epidermis of skin. Epidermal basal cells 
show distinct LASP1–positivity. In the dermis, histiocytes (yellow arrow) and cut blood vessels 
(red arrow) exhibit LASP1 expression. (B) Interspersed melanocyte cells in the consecutive 
section stained with MART1 antibodies. Sections were counter stained with hematoxylin and 
eosin. (Magnification 20X; Scale bar = 100 µm) 
The cells in stratum basale divide, differentiate and migrate towards the surface (stratum 
spinosum) and in these cells a positive LASP1 nuclear staining is also observed (Figure 
11). But the cells in the layer spinosum and granulosum are lacking LASP1 staining 
(Figure 11). 
 
Figure 11: LASP1 nuclear positive basal cells in the epidermis. (A) Magnification 20 X; Scale 
bar = 100 µm (B) the marked section in 100 X magnification; Scale bar = 10 µm. (LASP1–positive 
nuclei: white arrowheads, LASP1–negative nuclei: black arrowheads). Nuclear localization of 
LASP1 is present in stratum basale and is absent in the upper layers (stratum spinosum and 
stratum granulosum).  
Melanocytic nevi – the benign tumor of melanocytes are important markers for the risk of 
melanoma development. The analyzed samples of melanocytic nevi exhibited a very 
high expression of LASP1 in MART1–positive melanocytes. The consecutive sections of 
nevi samples stained with LASP1 and MART1 antibodies are depicted in Figure 12. In 
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contrast to melanocytes in the basal layer, melanocytic nevi samples are devoid for 
nuclear LASP1 (Figure 13).  
 
Figure 12: Depicted images of melanocytic nevi. Paraffin–embedded consecutive sections of 
nevi were subjected to immunohistochemistry with specific antibodies. (A) LASP1 
immunostaining. (B) MART1 staining. LASP1 shows an extremely intense staining in 
melanocyte–positive nevus cells (Magnification 20 X; Scale bar = 100 µm). 
 
Figure 13: Nuclear LASP1–positivity is absent in melanocytic nevi. (Magnification 100 X; 
Scale bar = 10 µm)  
1.2. LASP1 protein expression level in melanoma cell lines and NHEM 
To estimate the LASP1 protein expression level, Western blotting was done in nine 
melanoma cell lines and in a normal human epidermal melanocytes (NHEMs) cell line. 
All cell lysates were immunoblotted against LASP1 and β–Actin, which serves as a 
loading control. Figure 14 illustrates the graphical representation of the LASP1 to actin 
ratio in different analyzed cell lines and the respective Western blots. All tested 
melanoma cell lines and the NHEMs express a distinct LASP1 level.  
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Figure 14: LASP1 expression in melanoma cell lines and in normal human epidermal 
melanocyte (NHEM). Graphical presentation of LASP1 to β–Actin ratio in nine melanoma cell 
lines and in NHEMs is shown. Representative immunoblots for LASP1 protein in each cell lines is 
depicted below the graph.  β–Actin served as loading control. The status of tumor suppressor, 
p53 oncogene is also noted.  
In the former studies it has been shown that the tumor suppressor p53 regulates the 
expression of LASP1 protein (Wang, Feng et al. 2009). Therefore validated p53 status in 
all these cell lines and are presented in Figure 14. However, no functional repression of 
LASP1 by wild type (wt) p53 is noticed.  
 
Figure 15: Bright field image of pigmented MaMel2 cells. (A) MaMel2 cell under culture 
condition (Magnification 32X). (B) MaMel2 cell fixed in paraformaldehyde (Magnification 60X).  
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For further experiments, MaMel2, a melanotic cell line derived from a subcutaneous 
melanoma metastasis with high LASP1 protein levels and UACC257, a slightly melanotic 
primary melanoma cell line, along with NHEM cells, were considered. The bright field 
image of a MaMel2 cell under cell culture conditions as well as a formaldehyde fixed cell 
are illustrated in Figure 15. The visible tiny black spots are melanosomes. The level of 
pigmentation in MaMel2 cells was observed to increase with cell culture passages. 
Pigmentation difference in MaMel2 cells in passage 1 and passage 4 is shown in Figure 
16. 
 
Figure 16: Passage–dependent pigmentation difference in MaMel2 cell pellets. (A) Passage 
1 and (B) Passage 4 is presented. Pigmentation level in cells increases with cell culture 
passages.  
Transfection was performed in normal human epidermal melanocytes (NHEMs) using 
metafectene reagent, but as shown in Figure 17 A, LASP1 depletion was not successful 
in NHEM cells.  Knockdown experiments in melanoma cell lines were found to be perfect 
with cells in passage 2 to 6 (Figure 17 B). Taken together these two facts (pigmentation 
and LASP1 silencing) all experiments were done with cells from passage 2 to 6.  
    
Figure 17: LASP1 depletion in melanocyte and melanoma cell. (A) Representative Western 
blot of LASP1 knockdown in NHEMs. Transfection of LASP1 siRNA using metafectene 
transfection reagent did not work in NHEMs. (B) A maximum silencing was observed in MaMel2 
cells using metafectene after 72 hr of transfection. β–Actin serves as loading control.  
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2. LASP1 knockdown influences cell migration and proliferation 
Previous studies have demonstrated that LASP1 plays an important role in cell viability, 
motility and tumor dissemination (Raman, Sai et al. 2010; Traenka, Remke et al. 2010; 
Tang, Kong et al. 2012; Zhao, Ren et al. 2015), and also nuclear localization positively 
correlated with aggressive, proliferative cell growth and a transcriptional function or role 
in cell cycle control is discussed. Since a distinct LASP1 expression and a positive 
LASP1–nuclear immunostaining noticed in the basal cells of the epidermis, this study 
focused on the functional role of LASP1 in melanocytes.  
 
Figure 18: The effect of LASP1 silencing on proliferation, adhesion and migration.  
Melanoma cell lines– UACC257 and MaMel2 were transfected with siRNA against LASP1 and 
control siRNA and were cultured for 72 hr. Post transfection cells were harvested and assayed 
(protocol explained in the methods section) and the measured absorbances are presented in 
percentages. LASP1 depletion was confirmed by Western blot.  
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Therefore, in order to study LASP1 role on proliferation, adhesion and migration, 
melanoma cell lines – UACC257 and MaMel2 were transiently transfected with siRNA 
against LASP1 or control. As shown in Figure 18, an effectual reduction in the LASP1 
protein level (~75%) was observed after 72 hr. The effect of LASP1 silencing on these 
two cell lines, examined by using a modified Boyden–chamber for migration, a 
fibronectin adhesion assay and the MTT viability test are furnished in Figure 18. A 
distinct reduction of the migratory potential (~25%, p≤0.005) in combination with a weak 
but significant inhibition of proliferation (~10%, p≤0.001) was observed upon LASP1 
silencing (Figure 18). Although not significant, a modest decrease in adhesion (~15%; 
p>0.05) was detected. Unlike to the studies with other cancer cells, the observed 
influence of LASP1 on cell division and movement in melanoma cell lines is low.  
3. LASP1 – dynamin interaction at melanocyte dendrite tips facilitate melanosome 
vesicle release   
In consideration of the presence of LASP1 in the basal cells of epidermal layer and the 
very high expression of LASP1 in melanocytic nevi, the investigator hypothesized about 
a melanocyte specific LASP1 function. The primary function of melanocytes is the 
production of the photo protective pigment melanin (Cichorek, Wachulska et al. 2013). 
Melanogenesis initiates with the pre-melanosome vesicle formation at the Golgi complex 
(Sitaram and Marks 2012), maturation of melanosome vesicle through four different 
stages with subsequent melanin synthesis and deposition on the fibrils followed by 
transport of the matured melanosome vesicle to the dendrite tips and finally melanin 
dense melanosome vesicles are released at the plasma membrane into the extracellular 
matrix (Costin and Hearing 2007). LASP1 can bind to various melanosome trafficking 
proteins like F–Actin (Chew, Chen et al. 2002; Watabe, Valencia et al. 2008) and 
dynamin (Chi, Valencia et al. 2006; Mihlan, Reiss et al. 2013) via its unique domain 
organization. Consideration binding of LASP1 to these proteins, protein depletion in 
melanocytes can influence intracellular melanin level by regulating either melanogenesis 
pathway or melanosome vesicle release processes. 
3.1 LASP1 depletion elevates intracellular melanin levels in MaMel2 cells 
independently of melanogenesis 
In order to scrutinize LASP1 involvement in melanogenesis, intracellular melanin level 
was measured in MaMel2 cells transiently transfected with LASP1 siRNA. Graphical 
presentation of melanin concentration in MaMel2 cells treated with control– or LASP1– 
siRNA is shown in Figure 19 A. siRNA transfection resulted in more than 90% silencing 
and a representative Western blot for LASP1 knockdown is depicted in Figure 19 A. In 
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comparison to the control cells, a moderate but significant elevation of ~10%, in the 
cellular melanin amount was detected in LASP1 depleted cells (p=0.03) (Figure 19 A 
and B). 
 
Figure 19: LASP1 depletion increases intracellular melanin in MaMel2 cells. MaMel2 cells 
transfected with control– and LASP1– siRNA were harvested, cellular melanin was dissolved by 
incubating in 1N NaOH at 80
o
C and measured at 450nm. (A) Graphical representation of the 
intracellular melanin level (~10% increase in LASP1 knockdown cells, p=0.03) in percentage and 
immunoblots of the corresponding samples against LASP1 and β–Actin (loading control), 
tyrosinase and TRP1 (melanogenesis regulators, not affected) are depicted. (B) Pellets from 
control and LASP1 knockdown MaMel2 cells after 72 hr of transfection. 
Tyrosinase and tyrosinase related protein 1 (TRP1) are two important proteins for 
melanin synthesis and the generation of mature melanosome is highly dependent upon 
the cellular abundance of these two proteins (Sitaram and Marks 2012). The expression 
levels of these two melanogenesis regulators were examined to analyze whether the 
increased melanin amount is due to the cellular melanogenesis. Notably, as shown in 
Figure 19 A, no change is observed in the expression levels of both proteins. These data 
confirmed that the monitored accumulation of melanin content in LASP1 depleted cells is 
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not due to the de novo melanogenesis pathway as the melanogenesis regulators 
remained unaffected by these experiments, presuming a hindrance in melanin release. 
3.2. LASP1 co-localizes with tyrosinase and dynamin at the dendrite tips of the 
cells 
Immunofluorescence experiments were conducted to further check association of LASP1 
with melanosomes and also to study its participation in melanin release. Tyrosinase, a 
melanosome specific marker was used to analyze the localization of LASP1 with 
melanosomes. Figure 20 presents the co-localization of LASP1 with the melanosome 
specific marker tyrosinase in different cell lines. Although a clear staining for tyrosinase 
displayed along the perinuclear vesicles and at the dendrite tips, co-localization with 
LASP1 was shown only at the dendrite tips of the melanocytes; assuming that LASP1 is 
associated with late stage melanosomes.  
Next step was taken to check LASP1 involvement in melanosomes vesicle release at the 
dendrite tips. LASP1 co-localization with dynamin, a well–known protein for its 
participation in clathrin coated vesicle trafficking was studied. Immunofluorescence 
images in Figure 21 demonstrate a distinct presence of dynamin mainly at the Golgi 
around the nucleus, along the cell membrane and at the tips. In agreement with the 
observed localization of LASP1 with tyrosinase, dynamin and LASP1 co-localizes only at 
the tips of the cells but not around the nucleus. These data further confirmed that LASP1 
is associated with late stage melanosomes and is involved in the melanosome vesicle 
release at the plasma membrane. Control experiments without primary antibodies 
revealed no staining with the secondary antibodies.  
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Figure 20: Subcellular distribution of LASP1 and tyrosinase in different cell lines. Cells 
were fixed in 4% formaldehyde, stained for indicated antibodies and counterstained with DAPI for 
nucleus. Immunofluorescence images showing LASP1 co-localization with tyrosinase (an enzyme 
that regulates melanogenesis) in NHEMs, MaMel2, and UACC257 cells. LASP1 (red), tyrosinase 
(green), DAPI (blue) and merged (yellow). Co-localization is observed at the dendrite tips of the 
cells.  
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Figure 21: Co-localization of LASP1 and dynamin in different cell lines. LASP1 co-localizes 
with dynamin (a protein involved in vesicle formation, trafficking and budding) at the dendrite tips 
in NHEMs, MaMel2, and UACC257 cells. LASP1 (red), dynamin (green), DAPI (blue) and merged 
(yellow).  
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4. Vesicle trafficking protein dynamin – a novel binding partner of LASP1 in 
melanocytes  
 
Pull-down assays were carried out to further investigate the observed co-localization of 
dynamin and tyrosinase with LASP1 demonstrated by immunofluorescence and to 
analyze a possible binding interaction of the proteins.  
 
4.1. GST–LASP1 production 
The E.coli strains expressing GST–LASP1 fusion gene were stimulated with IPTG and 
the protein was purified using GST beads. To dissect the expression of the purified 
GST–LASP1 protein, samples from every step of preparation and purification were 
analyzed and are presented in Figure 22 A. E.coli strains carrying GST–control vectors  
 
Figure 22: Screening of the expression level of proteins in GST overexpression 
experiments. Coomassie brilliant blue staining for protein expression levels at the expected 
molecular weight for (A) GST– LASP1 and control beads (protocol detailed in methods section) 
(B) Concentration check using bovine serum albumin (BSA) as standard (10–1000µg). 
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were also processed in a similar manner and the GST–control beads are shown in 
Figure 22 A. In Figure 22 B depicted the concentration of the purified protein in 
comparison to BSA standards (10 µg–1000 µg). The GST– control and LASP1 beads 
thus produced were used for the subsequent pull-down assays.  
 
4.2. Pull-down assay 
After GST–LASP1 production, pull-down assays were performed to validate the 
observed co-localization of LASP1 with dynamin and tyrosinase. MaMel2 cell lysate 
incubated with GST– control and LASP1 beads was analyzed for specific protein binding  
 
 
Figure 23: Dynamin a novel binding partner of LASP1 in melanocytes. (A) Pull-down studies 
demonstrate binding of dynamin to GST–LASP1 beads in NHEM and MaMel2 cell homogenates. 
But no binding of tyrosinase and Rab27A to GST–LASP1 was observed. Zyxin (positive control, 
known binding partner of LASP1) and histone H2B (negative control) served as controls for the 
experiment. (B) Western blot analysis of dynamin protein expression in NHEM and in melanoma 
cell lines, along with LASP1, β–Actin as loading control.  
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and data are shown in Figure 23 A. A concrete binding of dynamin to GST–LASP1 was 
detected while no binding to tyrosinase or Rab27A (a second melanosome marker that 
regulates the peripheral distribution of melanosomes in melanocytes) (Bruder, Pfeiffer et 
al. 2012) could be observed. Binding of zyxin, a known LASP1 interacting partner (Li, 
Zhuang et al. 2004) to GST–LASP1 beads served as positive control and histone H2B (a 
nuclear protein) acted as negative control for the experiment. Similar results were also 
achieved with UACC257 and NHEM cells. These results identified dynamin as a novel 
binding partner of LASP1 in melanocytes while LASP1 only co-localizes with tyrosinase, 
most likely at melanocytes.  
Figure 23 B furnishes the expression pattern of dynamin in different melanoma cell lines 
and in NHEMs. All analyzed melanoma cells show a higher expression of dynamin than 
NHEMs. However, no correlation is observed between the pigmentation status and 
dynamin expression in these tested cells. The high dynamin level in amelanotic cells, for 
instance SKMel5, is explained by protein involvement in melanosome vesicle formation 
at the Golgi complex.  
5. LASP1 and dynamin – two novel proteins associated with mature late stage 
melanosomes  
To prove that LASP1 is associated with late stage melanosomes or stage IV 
melanosomes, the different stages of melanosomes were separated, purified and 
analyzed by sucrose density gradient centrifugation. Basically, the experiment takes 
advantage of density differences of melanosomes in various stages to purify these 
organelles over stepwise density gradients from 1.0 to 2.0 M sucrose (Watabe, 
Kushimoto et al. 2005).  
5.1. Isolation and purification of melanosomal fractions by sucrose density 
gradient centrifugation 
Melanosomes mature within the melanocyte through four morphologically distinct stages 
(Raposo and Marks 2007) which are dispersed in 1.0 M–1.8 M sucrose density gradients 
during ultracentrifugation. Early melanosomes or pre-melanosomes are detected in the 
1.0 M and 1.2 M fractions while 1.6 and 1.8 M sucrose fractions contains late or matured 
melanosomes (Kushimoto, Basrur et al. 2001). Figure 24 shows a schematic 
representation of the procedure used to purify and characterize melanosomal proteins. 
Homogenate from pigmented MaMel2 cells were subjected to sucrose density gradient 
ultracentrifugation and the fractions obtained were further purified and analyzed by 
immunoblotting.  
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Figure 24: Layout of sucrose density gradient centrifugation protocol for melanosome 
isolation. Flowchart describes the method used to isolate melanosomes at various stages of 
maturation from pigmented MaMel2 cells. The ultracentrifuge tube illustrates fractions containing 
different stages of melanosomes. Stage I and II (1.0 and 1.2 M), stage II and III (1.4 M) and stage 
III and IV (1.6 and 1.8 M) are present in the fractions of sucrose gradient. 
5.2. Distribution of melanosomal proteins by immunoblotting 
The bulk of proteins, separated at very distinct and discrete parts of the sucrose density 
gradient, were subjected to Western blot analysis to illustrate LASP1 and dynamin being 
genuine melanosome vesicle associated proteins. Fractions examined included cytosol 
before and after centrifugation in 0.25 M sucrose solution and the 1.0, 1.2, 1.4, 1.5, 1.6 
and 1.8 M sucrose fractions. Immunoblotting of the fractions demonstrated the highest 
protein concentration in the low density 1.0 M and 1.2 M sucrose fractions and 
substantiates the existence of the two most stringent markers of melanosomes – 
tyrosinase and TRP1 in these fractions.  
Immunoblotting data shown in Figure 25 revealed that LASP1 and dynamin are present 
in the late stage of melanosomes. The high level of LASP1 in the low density fractions is 
due to smeared soluble protein from the loading sample as can be seen by high LASP1 
in the “cytosol after” centrifugation fraction (Figure 25). Likewise, the presence of LASP1 
in the initial fractions is not consistent with the immunofluorescence images as there is 
no co-localization of LASP1 with tyrosinase and dynamin around the nucleus in stage I/II 
(Figure 20). Accordingly, the high level of dynamin in the initial gradient indicates the 
possible involvement of the protein in pre-melanosome formation from the Golgi 
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complex, as shown in the immunofluorescence of Figure 20 B. As depicted in Figure 25, 
tyrosinase is present nearly in all fractions while TRP1 is more abundant in fractions 
containing earlier stage melanosomes. 
 
Figure 25: Immunoblot analysis of sucrose density gradient purified fractions. MaMel2 cell 
cytosol was subjected to sucrose density gradient centrifugation. Purified fractions were blotted 
against LASP1, TRP1, tyrosinase and dynamin. Lanes correspond to cell cytosol (before and 
after centrifugation) and the different sucrose gradient fractions. The protein concentration of the 
fractions and the corresponding melanosome stages are stated. All four proteins exhibited a peak 
in 1.8 M fraction.  
As mentioned in previous study, in order to check the presence of other organelles, 
endoplasmic reticulum marker protein BIP (Binding Immunoglobulin Protein) was 
analyzed in different sucrose fractions. BIP is a molecular chaperone located in the 
lumen of the endoplasmic reticulum (Gething 1999) and was identified in the earlier 
protein rich fractions and in the 1.8 M fraction, which is in consonance with earlier finding 
(Kushimoto, Basrur et al. 2001). Table 10 represents the distribution pattern obtained by 
Western blotting of isolated melanosomal marker proteins and of the endoplasmic 
reticulum marker.  
In two out of four experiments, even dark melanosomes were visible in 1.8 M fraction 
(Figure 26). The evidence of LASP1 and dynamin in the final fraction of the gradient, 
along with tyrosinase and TRP1, confirms the association of these proteins with late 
stage melanosomes (stage IV) and is in agreement with the immunofluorescence data. 
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Interestingly, all four proteins show a second peak of increase in the 1.8 M sucrose 
fraction that corresponds to the stage IV melanosomes.  
 
Figure 26: Ultracentrifuge tube with dark melanosomes in 1.8 M sucrose fraction. 
Arrowheads shows dark pigmented melanosomes in the 1.8 M fraction of sucrose, after 
ultracentrifugation of MaMel2 supernatant on a discontinuous sucrose gradient. 
Table 10: Distribution of marker proteins by Western blotting 
Fraction  Stage   Tyrosinase   TRP1   ER (BIP) 
1.0 M sucrose  I, II  ++   ++  + 
1.2 M sucrose  I, II  ++   ++  + 
1.4 M sucrose  II, III  ++   +  ± 
1.5 M sucrose  II, III  +   +  ± 
1.6 M sucrose  III, IV  ±   ±  ± 
1.8 M sucrose  III, IV  +   +  +  
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5.3. LASP1 and dynamin co-localizes with tyrosinase in peripheral melanosomes 
As shown in Figure 27 LASP1 co-localizes with dynamin along the long dendrite of 
MaMel2 cells. The merged protein spots perfectly match with mature melanosomes in 
the bright-field. Similarly, at the periphery of NHEM cells, co-localization of LASP1 with 
tyrosinase is observed in accordance with the dark peripheral melanosomes visualized 
in the bright field (Figure 28). 
 
Figure 27: Co-localization of LASP1 and dynamin with peripheral melanosomes in MaMel2 
cells.  MaMel2 dendrite showing immunostaining for LASP1 (red) and dynamin (green). LASP1–
dynamin co-localization (yellow) perfectly matches with the peripheral melanosomes in the 
bright–filed. Arrowheads are pointing the co-localization spots.   
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Figure 28: LASP1 co-localization with tyrosinase (melanosomes) in NHEM dendrite tips. A 
NHEM cell presenting the dendrite tip immunostained for LASP1 and tyrosinase. LASP1 (red) 
and tyrosinase (green) co-localizes (yellow) along the cell dendrites.  Bright–filed illumination of 
the dendrite tips displaying melanosomes corresponding to the co-localization (arrowheads).  
As mentioned previously, melanosome biogenesis starts with pre-melanosome formation 
from the perinuclear region and ends with release of mature melanosomes at the plasma 
membrane. Dynamin, a novel protein in melanocytes displays a characteristics 
distribution in the cells along with the melanosomal protein tyrosinase, where it is 
present on a population of vesicular structures in the perinuclear region and at the 
peripheral region (Figure 29). These results verified the involvement of dynamin in 
melanosomes vesicle formation at the Golgi and in the release at the dendrite tips of 
cells.  
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Figure 29: Subcellular distribution of dynamin and tyrosinase. Dynamin co-localizes with 
tyrosinase in the perinuclear and peripheral melanosomes. Dynamin (red), tyrosinase (green) and 
co-localization (yellow). Arrowheads represent co-localization with melanosomes. 
The merged images of all three proteins– LASP1, dynamin and tyrosinase perfectly co-
localizes with the representative dark melanosomes and the data substantiate the 
sucrose density gradient result, identifying LASP1 and dynamin in the 1.8 M fractions, 
along with the melanosomal proteins tyrosinase and TRP1. 
Summing up all results obtained thus far, the data revealed that LASP1, a newly 
identified scaffolding protein in melanocytes, is associated with late stage melanosomes 
and is involved in melanosome vesicle release at the dendrite tips along with the binding 
partner dynamin. 
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B. LASP1 protein impact on human melanoma cancer  
1. LASP1 protein expression pattern in melanoma 
The malignant transformation of melanocytes into cutaneous melanoma is considered to 
be the most aggressive form of skin cancer and has a high risk of metastases 
susceptibility (Bastian 2014). Melanoma can also develop from pre-existing melanocytic 
nevi. Considering the very high expression of LASP1 in melanocytic nevi and since an 
elevated level of LASP1 have been observed in almost all tested cancer entities and 
were found to be involved in tumor progression [reviewed in (Orth, Cazes et al. 2015)] 
the investigator hypothesized that LASP1 might also be involved in melanoma tumor 
progression. 
1.1. LASP1 expression decreases with melanoma cancer progression  
LASP1 protein expression pattern was examined in 29 melanocytic nevi, 58 primary 
melanoma and 20 metastatic melanoma specimens. For semi–quantitative 
Immunoreactive Score (IRS) assessment, immunohistological samples stained for 
LASP1 and MART1 were scored by two independent experts, based on the evaluation 
criteria explained in the method’s section (Remmele and Stegner 1987; Grunewald, 
Kammerer et al. 2007), and the data were kindly provided. Figure 30 illustrates 
representatives from each group for the detected LASP1 and MART1 immunoreactivity 
along with the normal skin specimen. Considering staining intensity and LASP1–
positivity, IRS for normal skin is calculated as 1 (Figure 30). 
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Figure 30: Immunohistochemical staining of LASP1 in normal skin, melanocytic nevi, 
primary and metastatic melanoma. Depicted consecutive sections from normal skin, 
melanocytic nevi, primary melanoma and metastatic melanoma immunostained against LASP1 
(left panel) and MART1 (right panel). The sections were counterstained with haematoxylin and 
eosin (magnification 20X; Scale bar = 100 µm). 
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For statistical determination of tumors, samples scored with cytosolic LASP1–IRS ≥3 
were classified as LASP1–positive. Surprisingly, analysis of the IRS revealed a very low 
expression of LASP1 in primary melanoma (13.8%) and in metastases (4.7%) in 
comparison to the analyzed nevi (62.0%). These data revealed that LASP1–positivity 
decreases with increased malignancy. In none of the samples a nuclear staining, 
characteristic for many aggressive LASP1–positive tumors, was observed. The 
assessed cytosolic and nuclear LASP1–positivity is depicted in Table 11. 
 
Table 11: LASP1 expression in melanocytic nevi, primary melanoma, and 
melanoma metastases specimens 
Specimens No. of patients LASP1 positive LASP1positive  
   (n)   cells, (IRS˃2)  nuclei, (≥10%) 
Nevi  29   18 (62.0%)  0 (100%) 
Melanoma  58   8 (13.8%)  0 (100%)  
Metastasis 20   1 (4.7%)  0 (100%) 
  
1.2. No correlation of LASP1 to the clinicopathological features in melanoma 
patients 
Provided data were further analyzed to determine a possible role of LASP1 in 
melanoma. Correlation of LASP1 expression to the clinicopathological characteristics in 
58 melanoma patients’ samples is listed in Table 12. There was no significant correlation 
observed between LASP1 expression and the parameters– gender, age, tumor stage 
(T2–T4), tumor depth or metastases. Nevertheless, a slight significant correlation (p 
value of 0.05) to the cancer related death (CRD) was noticed. 75% of the LASP1–
positive patients died (6 out of 8) compared to 38% of LASP1–negative patients (19 out 
of 50), suggesting a poor survival of melanoma patients with observed LASP1 
expression. However, the overall number of deceased LASP1–positive individuals (n=8) 
is too low for a statistically robust conclusion on CRD. 
  
Results 
 
- 72 - 
 
Table 12: Correlation of LASP1 expression to clinicopathological 
characteristics in 58 melanoma patients 
 
 
Parameter 
 
Melanoma 
 
LASP1 
Positive 
 
LASP1 
Negative 
 
p 
Number of patients 58 8 50  
 
Sex 
male 
female 
 
34 
24 
 
3 
5 
 
29 
21 
0.81 
Age at primary diagnosis  
≤ 60 
> 60 
22 
36 
1 
7 
21 
29 
0.13 
Lymph node metastases * 30 6 24 0.18 
Distant metastases * 28 6 22 0.11 
Tumor depth * (AJCC) 
1–2 mm (T2) 
2.1–4 mm (T3) 
>4 mm (T4) 
 
26 
13 
19 
 
3 
4 
1 
 
23 
9 
18 
0.1 
Cancer–related death ** 25 6 19 0.05 
 
* Tumor depth after AJCC guidelines. ** Within 5 years follow-up. Values of p were 
calculated by Chi-Square test; statistical significance is assumed when p<0.05. 
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2. LASP1 nuclear localization is absent in melanoma cell lines and NHEM  
Previous studies demonstrated a predominant nuclear localization of LASP1 in several 
cancer entities and were reported to correlate with worse long–time survival of patients 
in breast cancer (Frietsch, Grunewald et al. 2010). Although melanoma tissues show no 
nuclear LASP1 staining, the possibility of LASP1 to localize to the nucleus in melanoma 
cells was assessed. 
2.1. LASP1 is not localized within the nucleus in melanoma cell lines 
Stimulation with forskolin, results in an intracellular elevation of cAMP levels and 
concomitant activation of PKA, which leads to the downstream phosphorylation of 
LASP1 at Ser–146 and nuclear trans-localization of the protein (Mihlan, Reiss et al. 
2013). To investigate nuclear localization of LASP1, cytosolic and nuclear fractions were 
prepared from control– and forskolin–treated cells of NHEMs and melanoma cell lines– 
MaMel2 and UACC257. Similarly and as a positive control, fractions were obtained from 
the breast cancer cell line– MDAMB231 and were analyzed in parallel. As shown in 
Figure 31, LASP1 and pLASP1–S146 were localized exclusively in the cytosol of 
melanoma cell lines and NHEM, while in breast cancer cells a distinct nuclear LASP1 
signal was noticed. The purity of the cytosolic and nuclear preparations was controlled 
by the detection of lamin A/C or histone H2B (nucleus) and GAPDH (cytosol). The 
results confirmed the immunohistochemical data showing no nuclear LASP1 localization 
in melanocytic nevi, primary melanoma and melanoma metastases (Figure 30). 
 
Figure 31: Immunoblot analysis of nuclear and cytosolic fractions for LASP1 distribution. 
Cytosolic and nuclear fractions isolated from control and forskolin–stimulated cells were analyzed 
by Western blotting. Fractions from melanoma cell lines: MaMel2, UACC257, normal human 
epidermal melanocyte (NHEM) and breast cancer cell line: MDAMB231 were blotted with 
antibodies for LASP1, pSer–146 LASP1 (nuclear translocalisation), β–Actin (loading control), 
GAPDH (cytosolic marker), Lamin A/C or histone H2B (nuclear markers). Nuclear trans-
localization is absent in melanoma and melanocyte (NHEM) cells. 
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2.2. LASP1 interacting partners assisting in nuclear shuttling are absent in 
melanocytes  
It has been shown that LASP1 protein shuttles between the cytosol and the nucleus in a 
phosphorylation–dependent manner by binding to zonula occludens protein 2 (ZO2) 
(Mihlan, Reiss et al. 2013). To investigate the reason for the absence of nuclear LASP1 
trans-localization, the expression of proteins involved in cytoplasmic–nuclear shuttling 
was analysed. As seen in Figure 32, the tested melanoma cell lines MaMel2, SKMel5 
and NHEM do not express the LASP1 binding shuttle partner ZO2, as does the breast 
cancer cell line MDAMB231 (Figure 32). Unexpectedly, UACC257 cells express ZO2, 
though LASP1 is not detected in the nucleus. Protein kinase A (PKA) is expressed in all 
verified cell lines as shown in Figure 32.  
 
Figure 32: Western blot analysis of binding partners of LASP1 in cell lines. Expression 
pattern of ZO2, PKA and zyxin along with LASP1 was verified in melanoma cell lines and NHEMs 
and were compared with breast cancer cells– MDAMB231. Equal loading was adjusted using β–
Actin. 
Concluding the section, cutaneous melanoma is considered as the first tumor tested 
hitherto, showing no LASP1 overexpression. The protein is not involved in the 
development and progression of melanoma.  
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Discussion 
Skin is the body’s largest organ giving protection from ultraviolet radiation induced DNA 
damage and hence plays an essential role in human survival. As illustrated in Figure 33, 
skin has a complex structure and the most important layer is the highly proliferative and 
migrating stratum basale of epidermis. This is the first study demonstrating the existence 
of the scaffolding cytoskeletal protein, LASP1 in the pigment producing melanocytes of 
the skin. 
 
Figure 33: Schematic presentation of skin structure. Illustrated the complex structure of skin 
and inset a small portion of epidermal basal layer is depicted demonstrating basal cells and 
melanocytes. 
Source: http://www.uchospitals.edu/online–library/content=CDR552637 
In immunohistochemistry, LASP1 displays a positive staining in the highly proliferating 
stratum basale (Figure 9 B) while cells of superficial layers (stratum spinosum and 
stratum granulosum) exhibit no LASP1 expression (Figures 9 & 10). This finding 
resembles to the previous report showing LASP1 existence in human breast epidermal 
basal cells (Grunewald, Kammerer et al. 2007). Interestingly, a distinct nuclear 
localization is also detected in these basal cells (Figure 11). Previously it has been 
shown that the nuclear localization of LASP1 is associated with proliferation as well as 
cell cycle mechanism of the cells (Frietsch, Grunewald et al. 2010; Traenka, Remke et 
al. 2010) and the data also suggested a possible, but not yet proven, transcriptional 
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function. As the basal cells of the epidermis are highly proliferative, LASP1 is presumed 
to participate in the proliferation and also migration of these cells towards the upper layer 
of the skin.  
Since the knockdown experiments in normal human epidermal melanocytes were not 
successful, cell based assays were performed in human melanoma cell lines. In vitro 
experiments exploiting RNA interference strategy were carried out to analyze LASP1 
protein influence on proliferation, adhesion and migration. Proliferation rates of the cells 
decreased significantly at 10% upon LASP1 depletion and a distinct reduction in the 
migratory processes by more than 25% was observed (Figure 18). These data justify the 
noted presence of LASP1 in the highly proliferating and migrating basal cells of the 
epidermis (Figure 11).   
LASP1 protein has been bespoken to have an elevated level of expression in several 
cancer entities and participates in the development of tumor metastases (Grunewald, 
Kammerer et al. 2007; Frietsch, Grunewald et al. 2010; Wang, Zheng et al. 2012; Wang, 
Li et al. 2013) and is also documented to serve as a prognostic tumor marker for cancer 
detection, for example in medulloblastoma (Traenka, Remke et al. 2010) and 
hepatocellular carcinoma (Wang, Li et al. 2013).  
 
Figure 34: LASP1 immunostaining in tissue samples. (A) Normal skin (B) Melanocytic nevi 
(C) primary melanoma (D) melanoma metastases. 
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Intriguingly a very high expression of LASP1 is detected in benign melanocyte (Figures 
12 & 34 B). Surprisingly and in contradiction to the tested tumor entities to date, 
immunohistostaining of primary melanoma revealed a very low LASP1 expression 
pattern and an even reduced level in metastases (Figures 30 & 34 C-D). Besides, the 
minor effects observed in melanoma cell lines on proliferation (~10%) and migratory 
processes (~25%) after 75% depletion of the protein are not that impressive when 
compared to other studied tumors. Knockdown of LASP1 in breast and gastric cancer, 
for example, led to more than 50% reduction in migration (Grunewald, Kammerer et al. 
2006; Zheng, Yu et al. 2014). Furthermore, no significant correlation between LASP1 
expressions to clinicopathological parameters in melanoma patients is observed (Table 
12). Although, no obvious correlation is noted to the melanoma prognostic factors like 
gender, age, tumor depth and metastases, a significance of p=0.05 is noticed to cancer 
related death (CRD) in LASP1–positive patients. Nevertheless, an overt decision on 
CRD is impossible due to the lack of considerable number of LASP1–positive patients 
(n=8).  
As explained in the Review of literature, various studies demonstrated that LASP1 
overexpression and nuclear localization are positively correlated with malignancy, tumor 
grade and metastatic lymph node status (Grunewald, Kammerer et al. 2007; Frietsch, 
Grunewald et al. 2010; Wang, Zheng et al. 2012; Wang, Li et al. 2013). However, a 
positive nuclear localization is absent in benign tumor – melanocytic nevi (Figure 13) and 
also in primary melanoma and melanoma metastases. The data are also supported by 
the in vitro LASP1 nuclear localization experiments, revealing no LASP1 nuclear 
localization in melanoma cell lines. 
Upon forskolin stimulation, LASP1 get phosphorylated at Ser–146 by PKA and 
translocated into the nucleus by binding to zonula occludens 2 (ZO2) in breast cancer 
cell line – MDAMB231 (Mihlan, Reiss et al. 2013). Similar study in the melanoma cell 
lines – MaMel2 and UACC257 did not reveal any nuclear trans-localization of LASP1 
after forskolin stimulation. The absence of LASP1 nuclear localization is also detected in 
chronic myeloid leukemia (CML), however, no mechanism is discussed (Frietsch, 
Kastner et al. 2014). Unexpectedly, NHEMs also showed no nuclear trans-localization of 
LASP1, which is contradictory to the observed nuclear expression of LASP1 in the basal 
cells of normal skin. 
A possible explanation for this discrepancy could be that LASP1 might have a 
melanocyte specific function rather than being involved in the human melanoma 
development and progression. Earlier researches have illustrated LASP1 participation in 
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various physiological activities in different cells, for instance, gastric parietal cells HCl 
secretion (Chew, Chen et al. 2008) and kidney ductal cell function (Chew, Parente et al. 
2000). 
The most striking and interesting fact is the very high LASP1 expression in melanocytes 
– both, in stratum basale of normal skin (Figure 9 B) and in melanocytic nevi (Figure 11) 
assuming a novel role of LASP1 protein in melanocyte function.  
 
 
Figure 35: Illustrated the epidermal melanin unit of skin. Melanocyte reside between the 
basal layer cells and through dendritic processes communicates with about 30–40 keratinocytes 
in the epidermal melanin unit. Melanocyte synthesizes melanin in melanosomes and delivered to 
keratinocytes to protect cells from UV radiation.  
Source:http://www.bloggang.com/mainblog.php?id=pupesosweet&month=19–02–2012 
&group=6&gblog=26 
 
The epidermal melanin unit of skin consists of a minority population of melanocytes and 
a majority of keratinocytes in proportion to 1:~40 (Hume and Seabra 2011) – as it is 
represented in Figure 35. The melanocytes and keratinocytes function in a symbiotic 
manner – melanocytes synthesize the coloring pigment melanin in specific organelles, 
termed melanosomes, and release these into the extracellular matrix where 
keratinocytes phagocyte these organelles, thereby forming a melanin nuclear cap and 
protecting the cells from UV irradiation [reviewed in (Cichorek, Wachulska et al. 2013)]. 
The principal function of melanocytes is the production of the coloring pigment melanin, 
thence the existence of LASP1 in melanocytes, strongly suggests an involvement of this  
protein in melanogenesis pathway comprising of melanosome formation at the Golgi 
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complex around the nucleus [reviewed in (Sitaram and Marks 2012)], maturation of the 
organelle, followed by melanin synthesis and deposition [reviewed in (Cichorek, 
Wachulska et al. 2013)], and finally transport of the melanosome organelle towards the 
dendrite tips of melanocytes and melanosome vesicle release at the plasma membrane  
(Hume and Seabra 2011). 
An elevated intracellular melanin level (10%) in LASP1 depleted cells despite an 
unaltered expression of the two melanogenesis regulator proteins tyrosinase and TRP1, 
suggests a partial hindrance in melanin release. Prior studies have proven that LASP1 
can bind to various melanosome trafficking proteins e.g. F–Actin (Chew, Chen et al. 
2002; Watabe, Valencia et al. 2008) and dynamin (Chi, Valencia et al. 2006; Mihlan, 
Reiss et al. 2013). These facts put forward strong reasons to examine the subcellular 
distribution of LASP1 in melanocytes and to analyze protein contribution in the steps of 
melanogenesis. 
Tyrosinase, a glycoprotein located in the melanosomal membrane, is defined as a 
melanosome specific marker as well as considered as the rate limiting enzyme for 
melanin synthesis [reviewed in (Raposo and Marks 2007; Park, Kosmadaki et al. 2009)].  
Immunofluorescence images, illustrating LASP1 co-localization with tyrosinase at the 
dendrite tips of cells, confirmed the existence of LASP1 in the pigment producing 
vesicles, and especially in late melanosomes (Figure 20 & 28). Dynamin is a well–known 
protein involved in clathrin–mediated vesicle trafficking and in membrane fission 
[reviewed in (Praefcke and McMahon 2004; Faelber, Held et al. 2012; Morlot and Roux 
2013)]. Additionally, LASP1 co-localization with dynamin along the melanocyte dendrites 
and at the cell tips (Figures 21 & 27), suggests a possible participation of LASP1 in late 
melanosome vesicle release at the plasma membrane. GST– pull-down studies 
confirmed the perceived co-localization of dynamin with LASP1 (Figure 23).  
In 2006, Chi et al. characterized melanosome proteomics by liquid chromatography / 
mass spectrometry and listed ~1500 proteins, amongst them LASP1 and dynamin as 
putative proteins in melanosomes, albeit the data had not yet been validated by any 
method (Chi, Valencia et al. 2006). This is the first study confirming now the presence of 
LASP1 and dynamin in melanocytes and in melanosomes in in vitro experiments. 
It has been demonstrated previously that melanosomes mature through four 
morphologically distinct stages I – IV. Melanosome isolation by sucrose density gradient 
and examination of the fractions by Western blot revealed the presence of LASP1 and 
dynamin in the 1.8 M sucrose fraction which comprises of late melanosomes in stage III 
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and IV (Figure 25). The detected band for dynamin in the early 1.0 M fraction explains its 
role in pre-melanosome (stage I) formation and is also supported by the IF images 
displaying dynamin staining around the nucleus (Figure 21). Moreover, co-localization of 
dynamin with tyrosinase further confirms its presence in perinuclear and peripheral 
melanosomes (Figure 29). Besides, dynamin is determined as a novel binding partner of 
LASP1 in melanocytes (Figure 23). 
The major melanosomal proteins of tyrosinase gene family ̶ tyrosinase and tyrosinase 
related proteins 1 and 2 (TRP1 and TRP2) get glycosylated at the trans–Golgi network 
and are then directed to the ellipsoidal pre–melanosomes to modulate tyrosinase activity 
[reviewed in (Ghanem and Fabrice 2011)]. Researches have evidenced that both 
proteins are predominately present at stage III and IV of melanosomes (Raposo and 
Marks 2007). Concordant with the previous reports, the immunoblot analysis in this study 
revealed the distinct presence of TRP1 in the initial fractions of the sucrose gradient and 
the presence of tyrosinase in almost all fractions (Kushimoto, Basrur et al. 2001). 
Besides, all proteins unveiled a second peak in the 1.8 M fraction of the sucrose gradient 
which corresponds to stage IV or late stage melanosome (Figure 25). The data 
delineated in Table 10 are in agreement with a previous publication (Kushimoto, Basrur 
et al. 2001) for organelle markers. 
Piling up all evidences, the data firmly suggest that LASP1 is associated to the late stage 
melanosomes and is involved in melanosome vesicle release at the plasma membrane. 
Evident mechanisms by which melanocytes transfer melanin to keratinocytes is, thus far, 
unknown, but are explained in view of exocytosis processes in neuronal cells and cells of 
hematopoietic lineage which are analogues to melanocytes (Van Den Bossche, 
Naeyaert et al. 2006). LASP1 expression has been reported previously in neurons and 
has shown to concentrate at the synaptic terminals, where the release of 
neurotransmitters occurs (Phillips, Anderson et al. 2004). These data recommend a 
potential role of LASP1 in the complex release mechanisms taking place at the dendrite 
tips of the melanocyte cells. 
A diagrammatic model based on the previously explained mechanisms (Orth and 
McNiven 2003; Anitei and Hoflack 2012) illustrates a possible involvement of LASP1 in 
the F–Actin  ̶  dynamin mediated vesicle fission processes at the melanocyte dendrite 
tips (Figure 36). In 1992, Cerdan et al. identified first time the release of melanin occurs 
in specific melanocytic vesicles (Cerdan, Redziniak et al. 1992). Later Ando et at. 
confirmed that melanosomes are shed in membrane bound pigment globules, containing 
multiple melanosome vesicles (Ando, Niki et al. 2011; Ando, Niki et al. 2012).  
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Figure 36: Proposed model for LASP1 involved actin – dynamin mediated melanosome 
vesicle scission at melanocyte dendrite tips. In anterograde melanosomal transport mature 
melanosomes move along microtubules by means of the motor protein kinesin and were 
transferred towards the cell periphery. Once at the periphery, track switching from microtubules to 
actin filaments occurs which is mediated by Rab27A and myosin Va, a molecular motor protein 
and thus the complex gets coupled to the actin (1). In this fashion microtubule, actin filaments and 
motor systems co–operate to promote melanosome transport and to retain the organelle in 
peripheral dendrites. LASP1 and dynamin are present at actin mesh at the plasma membrane. 
LASP1 binds to actin and dynamin through its nebulin repeat and SH3 domain, respectively. 
Dynamin exits as a dimer and binds to actin through the stalk region (2). WASP and CDC42 
mediated activation of ARP2/3 lead to the branched polymerization of actin filaments towards the 
release site. Actin, together with other motor proteins, pushes the plasma membrane and 
enhances membrane invagination (3). As an adaptor/scaffolding protein, LASP1 recruits and 
positions dynamin at the tubular membrane (4). Subsequent polymerization of dynamin around 
the membrane in a helical manner together with GTP hydrolysis results in membrane constriction 
and melanosome vesicle scission at dendrite tips (5 and 6). 
The stage IV mature melanosomes are transported towards the periphery of the 
melanocytes along microtubules by kinesin and then track switching from microtubules 
to the actin mesh occurs. Later, melanosome complexes get coupled to the actin 
filaments via Rab27A and myosin Va motor proteins and then get driven centrifugally to 
the scission sites at dendrite tips (Hume and Seabra 2011). A first step in vesicle 
budding is the induction of membrane curvature and membrane tubulation at scission 
site. F–Actin polymerization mediated by ARP2/3, N–WASP and CDC42, supports the 
Discussion 
 
- 83 - 
 
processes of curvature formation and tubulation of the site (Orth and McNiven 2003; 
Anitei and Hoflack 2012) 
 
Figure 37: Representation of the domain organization of Dynamin. Linear representation of 
the dynamin structure as revealed by crystallographic studies (numbers indicate amino acid 
position within the primary sequence). The proline rich motif of dynamin (PRD) interacts with the 
SH3 – domain of LASP1.  
Dynamin is a 100 kDa protein comprising of an amino–terminal G domain; a 'middle' or 
'stalk' region; a pleckstrin homology domain (PH domain); a GTPase effector domain 
(GED) and a proline–rich carboxy–terminal region (Praefcke and McMahon 2004; 
Ferguson and De Camilli 2012; Morlot and Roux 2013). The domain structure of 
dynamin is illustrated in Figure 37, and it has been mentioned previously that the proline 
rich motif of dynamin interacts with the SH3 domain of LASP1 (Okamoto, Li et al. 2002). 
Dynamin has previously been characterized as a phosphoprotein in nerve terminals at 
the position of neurotransmitters release. Several researches demonstrated the 
involvement of dynamin in vesicle fission, both in endocytosis and in exocytosis. 
Dynamin functions by the oligomerization−dependent GTPase activation and also shows 
affinity to interact with lipid membranes (Praefcke and McMahon 2004).  
The possible actin–dynamin mediated vesicle budding at the plasma membrane is 
comprised of a series of steps – attachment of the melanosome to the actin mesh, 
membrane curvature and tubulation via tension generated by actin polymerization, 
followed by dynamin positioning at the tubular membrane as well as dynamin mediated–
membrane constriction and finally melanosome vesicle fission. The involvement of actin 
in the membrane curvature and the membrane constriction by dynamin have been 
mentioned in many studies (Orth and McNiven 2003; Heymann and Hinshaw 2009; 
Anitei and Hoflack 2012).  
The model hypothesizes LASP1 being a scaffolding/adaptor protein, interacting with 
dynamin through the SH3 domain and later recruiting dynamin from the actin mesh to 
the tubular edges of the plasma membrane. Afterwards, dynamin binds via the PH 
domain to the phospholipids of the plasma membrane, and subsequent, GTPase 
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dependent oligomerization results in the formation of a helical ring around the tubular 
membrane. Eventually conformational changes in the dynamin oligomer leads to 
membrane constriction and ultimately results in vesicle fission [reviewed in (Praefcke 
and McMahon 2004; Faelber, Held et al. 2012; Ferguson and De Camilli 2012)]. The 
functioning of dynamin by GTP hydrolysis and membrane twisting of vesicle neck during 
vesicle scission has been demonstrated through live microscopy based assays and in 
vitro immunogold assay (Jakobsson, Ackermann et al. 2011; Faelber, Held et al. 2012).  
As quoted before, participation of LASP1 in a similar mechanism has also been denoted 
in gastric parietal cells. A cAMP–dependent phosphorylation of LASP1 alters interaction 
with F–Actin and/or endocytic proteins and redistribution of LASP1 led to translocation of 
the protein to canalicular region. The authors also suggested the possibility that LASP1 
can serve as a vehicle for translocation of transport associated proteins to different 
functional regions within cell (Chew, Parente et al. 2000; Okamoto, Li et al. 2002).  
Though other factors may also assist for the action of dynamin, the present study 
illustrates that LASP1 and dynamin are newly identified proteins in melanosomes and 
that LASP1 is involved in the process of recruiting dynamin at the scission site for 
melanosome release.  
Since melanocytes constitute a minority population in the stratum basale of epidermis, 
an efficient transfer of melanosomes (melanin laden) to keratinocytes is crucial in the 
process of skin photoprotection. Numerous researches exemplified defects in 
melanosome transfer that lead to multifarious disorders. Therefore, understanding the 
nature of this process has great importance in clinical implications. The proposed model 
is likely to be helpful to enlighten two newly identified partners in the mechanism of 
melanosome vesicle release and might have some hints for the underway researches.   
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Annexure  
List of Units 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Symbols Units 
A Ampere 
∼ Approximate 
oC Degree Celsius 
DC Direct current 
g Gram 
hr Hour 
kDa Kilodalton 
l Liter 
µl Microliter 
µm Micrometer 
µM Micromolar 
mg Milligram 
ml Milliliter 
mM Millimolar 
min Minute 
M Molar 
nm Nanometer 
OD Optical density 
% Percentage 
g Relative centrifugal force 
sec Second 
V Voltage 
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